IMO -2125  Page 1 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 March  2018  
Confidential  PROTOCOL 2125 -204 
Study Title  A Phase 1/2 Study to Assess the Safety and Efficacy of 
Intratumoral IMO -2125 in Combination with Ipi[INVESTIGATOR_707122]:  IMO -2125  
IND Number:  [ADDRESS_960741] Number  2017 -003329 -14 
Sponsor:  Idera Pharmaceuticals, Inc.  
[ADDRESS_960742] 
Cambridge, MA [ZIP_CODE]  
Protocol Number:  2125 -204 
Protocol Version:  8.0 
Date:  27 March  2018 
Statement of Confidentiality  
This document contains Idera Pharmaceuticalsâ€™ privileged or confidential information and 
is provided to you as an Investigator, potential Investigator, or consultant, solely for review 
by [CONTACT_10825], your staff and applicable institutional review board(s). The information is not to be 
disclosed to others without written authorization from Idera Pharmaceuticals, Inc.  

IMO -2125   Page 2 of 106 
Protocol 2125- 204, Version 8.0  Date: [ADDRESS_960743] read the protocol, including all appendices and the Investigator â€™s Brochure, and I agree 
that it contains all necessary details for me and my staff to conduct this study as described. I will 
personally oversee the conduct of this study as outlined herein and will make a reasonable effort 
to complete the study within the time designated.  
I will provide all study personnel under my supervision with copi[INVESTIGATOR_707123], Inc. I will discuss this material with them to 
ensure that they are fully informed about IMO -2125, the safety parameters, and the conduct of 
the study in general. I am aware that, before commencement of this study, the institutional 
review board responsible for such matters must approve this pr otocol in the clinical facility 
where it will be conducted. I agree to make all reasonable efforts to adhere to the attached 
protocol. 
I, or my designee, agree to be present at all site- initiation visits and I nvestigator meetings. In 
addition, I will ensur e the presence of all relevant study personnel under my supervision at these 
visits and meetings.  
I agree to provide all patients with informed consent forms, as required by [CONTACT_707231]. I further agre e to report to Idera 
Pharmaceuticals, Inc. any adverse experiences in accordance with the terms of this  protocol and 
FDA (or applicable regulatory agency) regulations . 
 
 
Principal Investigator [CONTACT_5627] (print)    
 
 
 
   
Signature   [CONTACT_1782]  
 
,02 3DJH RI
3URWRFRO9HUVLRQ 'DWH0DUFK
&RQILGHQWLDO3URWRFRO$SSURYDO3DJH
6WXG\7LWOH $3KDVH6WXG\WR$VVHVVWKH6DIHW\DQG(IILFDF\RI,QWUDWXP RUDO
,02LQ&RPELQDWLRQZLWK,SLOLPXPDERU3HPEUROL]XPDELQ3DWL HQWV
ZLWK0HWDVWDWLF0HODQRPD
3URWRFRO1XPEHU 
3URWRFRO9HUVLRQ 
'DWH 0DUFK
,WKHXQGHUVLJQHGKDYHUHDGDQGDSSURYHWKLVSURWRFRODQGDJU HHRQLWVFRQWHQW
6KDK5DKLPLDQ0'
6U0HGLFDO'LUHFWRU0HGLFDO/HDG2QFRORJ\,GHUD 3KDUPDFHXWLFDOV,QF6SRQVRU5HSUHVHQWDWLYH'DWH
03/27/2018
IMO -2125   Page 4 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Version History  
Ver. No.  Approval Date  Comment  
1.0 23 June 2015  Initial submission  
2.0 08 September  2015  Revisions based on Food and Drug Administration  review and MD Anderson 
Cancer Center Clinical Research Committee review  
3.0 11 January 2016  Revisions made in order to align patient management with the labeled safety 
guidance for ipi[INVESTIGATOR_125] (YervoyÂ®, USPI) and current pi[INVESTIGATOR_707124], as well as administrative updates and 
updates for clarity.  
4.0 10 May  2016  Revisions made to include IMO -2125  + pembrolizumab (KeytrudaÂ®, USPI) as a 
new treatment arm and to modify the secondary and exploratory 
objectives/endpoints Additional clarity around the rationale for study design and 
administrative changes have also been provided .  
5.0 30 November  2016 â€¢ Removed Phase 2 randomization and the concurrent start of the two Phase 2 
treatment arms to expedite the initiation of the Phase 2 ipi[INVESTIGATOR_125] + 
IMO -2125 treatment arm.  
â€¢ Allowed enrollment of additional Phase 1 cohorts at previously studied doses 
of IMO -2125 to facilitate selection of the RP2D(s).  
â€¢ In Phase 2, switched from irRC to irRECIST for objective response 
assessments.  
â€¢ Modification to enrollment criteria to provide a more homogeneous population 
for the primary efficacy analysis .  
â€¢ Added optional tum or biopsy at Week 1.  
6.0 29 March  2017 â€¢ Extend ed the IMO -2125  treatment period to 9 doses to further evaluate the 
safety and clinical effects of IMO -2125 in patients with metastatic melanoma.  
Delayed responses to treatment (>12 weeks after the start of treatment) have 
been noted in advanced melanoma patients treated with immunotherapy agents 
(Wolchok, 2009). To further evaluate safety and potential clinical responses to 
treatment with IMO -2125, Protocol Amendment 2125- 204 Version 6.0 
extends the IMO -2125 treatment period.  
â€¢ Updated PK schedule.  
â€¢ Introduce d the possible addition of cohorts for new immunotherapy 
combinations. Immunotherapy for the treatment of metastatic melanoma is a 
rapi[INVESTIGATOR_707125]. There are new immunotherapy agents currently under 
investigation with some recently approved for marketed use. To expand the 
potential options for IMO -2125 development, the Sponsor may enroll patients 
in additional Phase 1 cohorts to investigate  IMO -2125 in combination with 
other immunotherapi[INVESTIGATOR_014].  
â€¢ Corrections to irRC response assessments in Appendix 2  (Section  21.2).  
IMO -2125   Page 5 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    7.0 01 September  2017  â€¢ Allows for enrollment of patients  who have received prior ipi[INVESTIGATOR_125], 
(including the ipi[INVESTIGATOR_125]/PD -1 inhibitor combination) now that preliminary 
safety and efficacy objectives have been achieved in the more restricted 
ipi[INVESTIGATOR_125] -naÃ¯ve population 
â€¢ Increases the cohort size for the Phase 2 I MO-2125 + ipi[INVESTIGATOR_707126].  
â€¢ Updates pembrolizumab dosing to use the 200 mg fixed dose to be consistent 
with the current labeling as of July 2017.  
â€¢ Update s the list for selection priority of the injected tumors.  
â€¢ Updates Section  9.2.1  to include an optional biopsy of the non -injected lesion 
at Week 2.  
â€¢ Clarifies  that the concomitant medications reporting period starts at 30 days 
before the patient signs consent  (Section  10.7.1) . 
â€¢ Adds disease control rate (DCR) endpoint.  
â€¢ Clarifies  that the assessment of exploratory endpoints will be based on 
assessments at Week 23 not Week 29.  
â€¢ Correction to the type of two -stage design for Ph ase 2 in the Synopsis and 
Section  16. 
â€¢ Additional u pdates in Section  16 (Statistical Analysis Methods) correspond ing 
with the other updates.  
8.0 27 March  2018  â€¢ Update  Idera Medical Monitor contact . 
â€¢ Change response criteria used in the primary efficacy endpoint in the Phase 2 
portion of the trial.  
â€¢ Add patient reported outcomes (PRO) assessments  and corresponding 
statistical analys is text . 
â€¢ Inclusion of liquid -fill presentation of IMO -2125 as an option for use in the 
study . 
â€¢ Clarify post -treatment contraception use.  
â€¢ Clarify PK and cytokine sampling schedules . Please note the additional 
cytokine sam ple times on Day 1, [ADDRESS_960744] -dose and pre -dose on Cycle 1 
Week 2, to better characterize the IMO -2125  activity.  
â€¢ Add descriptions of immune -related AEs to be evaluated by [CONTACT_2728] . 
â€¢ Allow Idera to collect scans for potential central independent review . 
 
 
IMO -2125   Page 6 of 106 
Protocol 2125- 204, Version 8.0  Date: [ADDRESS_960745] INFORMATION  
 
Reporting of Serious Adverse Events (SAE s) 
 
Any SAE must be entered in the Medidata RAVE Electronic Data Capture (EDC) system within 
[ADDRESS_960746] then be captured on the back- up paper SAE form 
and reported by [CONTACT_87109] 24 hours  to:  
CRO: SynteractHCR, Inc.  
Fax: 760- 268-6500 
Phone:  760- 268-8200 
Email: [EMAIL_7944]  
 
See Section  11.1 (Adverse Events) for definition and reporting procedure for SAEs. 
 
 
Sponsor Medical Monitor:  
Shah Rahimian, MD  
Sr. Medical Director, Medical Lead (Oncology)  
Phone: 484- 348-1642 
Cell: 814- 691-7377 
Email: [EMAIL_13547]  
IMO -2125   Page 7 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    1. SYNOPSIS  
Name [CONTACT_790]/Company: Idera Pharmaceuticals, Inc.  
Name [CONTACT_791]: IMO -2125  
Title of Study: A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO -2125 
in Combination with Ipi[INVESTIGATOR_707127]: End of study will be  approximately  [ADDRESS_960747] patient in Phase 2 has commenced study treatment . Phase of development: 
Phase 1/2 
Rationale: IMO -[ADDRESS_960748] of Toll -like receptor (TLR) 9, stimulates both the innate and adaptive immune systems, 
and induces the expression of an array of endogenous cytokines and chemokines, including 
interleukin (IL) -1Î², IL -6, IL -12, interferon (IFN) -Î±, IFN -Î³, interferon gamma -induced protein 
(IP)-10, tumor necrosis factor  (TNF) -Î±, and monocyte chemoattractant protein -1 (MCP -1). Of 
note, activation of TLR9 by [CONTACT_58444] -2125 induces high levels of IFN -Î± from plasmacytoid dendritic 
cells (pDCs). This extensive profile of cytokines and chemokines results in the activation of both 
innate and adaptive immunity. Local innate immune activation through IMO -2125, administered 
by [CONTACT_707232] d infiltration of tumor -specific CD8+ 
T cells and synergize with systemic therapi[INVESTIGATOR_707128] T lymphocyte antigen- 4 
(CTLA -4)/programmed cell death -1 (PD -1) blockade, resulting in superior anti -melanoma 
activity. Ipi[INVESTIGATOR_142] a monoclonal antibody that binds to CTLA -4 and is used in the treatment 
of metastatic melanoma that cannot be treated surgically. Pembrolizumab is a PD -1-blocking 
antibody indicated for the treatment of patients with unrese ctable or metastatic melanoma. In 
combination, IMO -2125 with either ipi[INVESTIGATOR_707129] a novel therapy to 
benefit patients with metastatic melanoma.  
Objectives:  
Primary: The primary objective of Phase 1 is to characterize the safety and determine a 
recommended Phase 2 dose (RP2D) of IMO -2125 when administered in combination with 
ipi[INVESTIGATOR_707130]. The maximum tolerated dose ( MTD ) and RP2D for IMO -2125 may differ 
between the combination of IMO -2125 and ipi[INVESTIGATOR_707131] -2125 and 
pembrolizumab.  
The primary objective of Phase 2 is to assess preliminary clinical activity of IMO -2125 in 
combination with ipi[INVESTIGATOR_707132]2D(s) 
in patients with metastatic melanoma  that is not responsive to PD -1 inhibitor therapy , using  
Response Evaluation Criteria in Solid Tumors  (RECIST) v1.1.  
Secondary: The secondary objectives of Phase 1 are to determine the plasma pharmacokinetics 
(PK) of single -dose IMO -2125 and repeat -dose IMO -2125 administered by [CONTACT_707233][INVESTIGATOR_707133]. An additional secondary objective 
of Phase 1 is to describe any preliminary an titumor activity.   
The seco ndary objectives of Phase 2 are to further assess the safety and tolerability of 
IMO -2125 in combination with ipi[INVESTIGATOR_707134] -related Response 
IMO -2125   Page 8 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Evaluation Criteria in Solid Tumors (irRECIST) and RECIST v1.1, overall survival (OS), OS at 
6 and 12 months , progression- free survival (PFS),  PFS at 6 and 12 months, durable response rate 
(DRR) , duration of response (DoR) , and disease control rate (DCR) . 
Exploratory: The exploratory objectives of Phase 1 and 2 are to assess  patient reported 
outcomes (PRO ), pre - and post -treatment blood biomarkers , pre- and post -treatment tumor 
biopsies for immunologic assessment, and explore  any potential association between th ese 
biomarker measures and anti tumor activity.  In addition, anti -IMO -2125, anti -ipi[INVESTIGATOR_125], and 
anti-pembrolizumab antibody formation will be assessed . 
Endpoints  
Primary: The primary endpoint of Phase [ADDRESS_960749] v1.1.  
Secondary:   
The secondary endpoint s in Phase 1 are:  
â€¢ PK assessments for IMO -2125;  
â€¢ ORR assessed using irRC and RECIST v1.1  
The secondary endpoints in Phase 2 include:  
â€¢ Safety and tolerability (type and frequency of AEs, clinical laborat ory values, 
electrocardiograms [ECGs], and vital sign measurements) for each combination;  
â€¢ Duration of response using RECIST  v1.1;  
â€¢ ORR and duration of response using ir RECIST;  
â€¢ PFS, defined as time from the initiation of treatment to disease progression by 
[CONTACT_299602] v1.1, or death from any cause;  
â€¢ PFS at 6 and 12 months;  
â€¢ OS, defined as time from initiation of treatment to death from any cause;  
â€¢ OS at 6 and 12 months;  
â€¢ Durable response rate by [CONTACT_299602] v1.1, defined as the rate of complete  
response (CR) plus partial response (PR) lasting at least [ADDRESS_960750] 12 months of study;  
â€¢ Disease control rate by [CONTACT_299602] v1.1, defined as the rate of CR, PR, or 
stable disease (SD).   
Exploratory:  The p re- and post -treatment exploratory endpoints of Phase 1 and 2 include, but 
are not limited to,  PRO using the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire -CORE 30 (EORTC QLQ -C30), blood biomarkers (e.g., IFN -Î³ and  
other plasma cytokines) and tumor markers to assess any potential association between immune 
responses to IMO -2125 at the Week  8 tumor biopsy with tumor response in both injected and 
IMO -2125   Page 9 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    uninjected tumor lesions at Week  13 or at Week  23 (depending on the prot ocol version under 
which the patients were enrolled).  
Study design: This is a two  arm, open- label  Phase 1/[ADDRESS_960751] 
experienced symptomatic or confirmed radiographic progression during or after treatment with 
an anti -PD-(L)1 agent ( alone or in combination) will be eligible. Prior BRAF or MEK inhibitor 
treatment is not req uired. The s tudy will be conducted in two  parts : a dose -escalation portion 
(Phase 1) to evaluate safety and tolerability of multiple dose levels and a Phase 2 portion to 
assess preliminary efficacy.   
Phase 1:  The Phase 1 porti on of the study will explore escalating dose levels  of IMO -2125 ( from 
4 to 32 mg with de -escalation to 2 mg allowed  for each IMO -2125 combination) . For each 
cohort, IMO -2125 will be a dministered as a  once -weekly  intratumoral injection for 3 consecutive 
weeks  in Cycle 1 , followed by [CONTACT_707234] 5, 8, 11, 17, 23, and 29 ( Day 1 
of Cycles 2 through 7) . Both ipi[INVESTIGATOR_707135] 3  weeks beginning Day 1 of Cycle 1 Week 2 . Continued pembrol izumab dosing 
following the study period is permitted at the discretion of the Investigator  for patients in the 
IMO -2125 + pembrolizumab treatment arm. The dosing schedule is summarized for Phase 1 and 
Phase 2 in the table below.  
Schedule of dosing for Pha se 1 and Phase 2  
 Cycle  
 1 2 3 4 5 6 7 
Study week  1 2 3 4 5 6 7 8 9 10 11 12 13 17 23 29 
IMO -2125 + ipi[INVESTIGATOR_707136] -2125  X X X - X - - X - - X - - X X X 
Ipi[INVESTIGATOR_125]  - X - - X - - X - - X - - - - - 
IMO -2125 + pembrolizumab  
IMO -2125  X X X - X - - X - - X - - X X X 
Pembrolizumab  - X - - X - - X - - X  X1 
Note: On weeks when the combinations are administered, administration of ipi[INVESTIGATOR_707137], followed by [CONTACT_58444] -2125. IMO -[ADDRESS_960752] occur within a Â± 2 day window of the scheduled dosing 
day.  
1  For patients in the IMO -2125 + pembrolizumab treatment arm, continued pembrolizumab dosing per the approved 
product label is permitted at the discretion of the Investigator.  
 
Patients assigned to [ADDRESS_960753] 
not yet reached the end of the Treatment Period may receive the Week 17, 23, and 29 injections 
at the discretion of the treating I nvestigator .  
Each cohort will be monitored for the occurrence of dose -limiting toxicities ( DLTs ). The 
DLT  evaluation period will be Cycle 1 (Weeks 1 through 4) . If a patient discontinues study 
participation before the DLT evaluation period is finished due to reasons other than experiencing 
a DLT, that patient must  be replaced so that the cohort may be properly evaluated.  
There are 3 patients planned per cohort. During Phase 1 , the Sponsor will assign patients to a 
IMO -2125   Page 10 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    treatment arm ( IMO -2125  + ipi[INVESTIGATOR_707138] -2125  + pembrolizumab) by [CONTACT_9084]. The 
Sponsor will maintain a prioritization schedule for cohort assignment in a separate document. A 
Cohort Review Committee (CRC) will be convened prior to each dose level escalation to review 
the available data and provide recommendations on study conduct. After completing the D LT 
evaluations for all planned IMO -[ADDRESS_960754] monthly th roughout Phase 1 of the study. After completion of either 
Phase 1 treatment arm and determination of the RP2D for that arm, the Phase 2 portion for the 
completed t reatment arm may be initiated. It is not necessary for Phase 1 to be completed in both 
treatment a rms before Phase 2 is started. After Phase 2 in either treatment arm is initiated, the 
Sponsor will assign the  treatment arm, cohort, and phase for patients.  
Dose -limiting toxicity  evaluations and CRC reviews for any additional immunotherapy 
combination cohorts will be done as described for the ipi[INVESTIGATOR_707139]. 
Phase 2: The Phase [ADDRESS_960755]  v1.1, of IMO -2125  + ipi[INVESTIGATOR_125], IMO -2125 + pembrolizumab, 
and any additional combinations that are studied in Phase 1. The dose level of IMO -[ADDRESS_960756] 60 patients treated at the IMO -2125 + ipi[INVESTIGATOR_707140]2D . This will 
include at least 21 patients in the primary IMO -2125 + ipi[INVESTIGATOR_707141] -evaluable population 
and up to 20 patients in the secondary IMO -2125 + ipi [INVESTIGATOR_707141] -evaluable population.  
In the IMO -2125 + pembrolizumab Phase 2 cohort, enrollment will continue until  21 patients in 
the IMO -2125 + pembrolizumab efficacy -evaluable population have been treated at the 
IMO -2125 +  pembrolizumab RP2D .  
Phase [ADDRESS_960757] for clinically and statistically relevant clinical activity . A 
treatment arm will stop if an interim futility analysis shows th ere is insufficient evidence of a 
clinically relevant response rate after 10 patients (Stage 1).  
If a patient discontinues  treatment  before completing at least one  efficacy evaluation for reasons 
other than toxicity , then that patient will be replaced, with the replacement assigned to the same 
treatment arm and dose level as the patient who dropped out early.  
Combination therapy in Phase 2 will continue using the same schedule as Phase 1, as presented 
in the schedule of dosing table. 
Assessments will be con ducted as defined in the Schedule of Evaluations  (Table  1 and Table  2). 
Number of patients (planned): The study will enroll approximately 90 to 100 patients. It is 
estimated that approximately 30 patients will be treated in  the dose -finding portion of  Phase 1 
and approximately 60 to 70 additional  patients will be treated in the Phase  2 portion of the study.  
IMO -2125   Page 11 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Diagnosis and main criteria for inclusion and exclusion:    
These criteria apply to both the Phase 1 dose -escalation por tion and the Phase 2 portion of this 
study.  
Inclusion criteria  
1) Patients must have histologicall y confirmed metastatic melanoma with measurable, 
stage  III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease.  
2) Patients must have symptomatic or radiographic progression during or after treatment 
with a PD -(L)[ADDRESS_960758] PD -(L)[ADDRESS_960759] 21 days. 
b. Prior BRAF or MEK inhibitor treatment is not required. However, f or patients 
with known BRAF status:  
i. Those with BRAF wild  type may have had a maximum of  two previous 
systemic regimens for the treatment of melanoma .  
ii. Those with a BRAF mutation may have had a maximum of  three previous 
systemic regimens for the treatment of melanoma.  
c. Prior ipi[INVESTIGATOR_707142] . 
d. Previous treatment with either a PD -1 inhibitor (for patients enrol ling on the 
IMO -2125 +  pembrolizumab combination) or CTLA -4 inhibitor (for patients 
enrolling on the IMO -2125 + ipi[INVESTIGATOR_43809]) should not have been 
accompanied by [CONTACT_707235] (per 
USPI) .  
i. Patients with a history of Grade â‰¥ 2 gastrointestinal symptoms 
(e.g., diarrhea, colitis) during prior checkpoint inhibitor treatment should 
be discussed with the Idera Medical Monitor during the Screening Period 
before starting study treatment.  
3) Phase [ADDRESS_960760] two  measurable tumor lesions  â‰¥ 1.[ADDRESS_960761] one  measurable lesion (per 
RECIST v1.1) which may be the same site that is used for the intratumoral injections.  
4) Patients mu st be â‰¥ 18 years  of age . 
5) Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status 
â‰¤2. 
6) Patients must meet the following laboratory criteria: 
a. Absolute neutrophil count (ANC) â‰¥  1.5 x 109/L (1500/mm3) 
b. Platelet count â‰¥ 75 x 109/L (75,000/mm3) 
c. Hemoglobin â‰¥ 8.0 g/dL  (4.96 mmol/L)  
d. Serum creatinine â‰¤ 1.5 x uppe r limit of normal (ULN) or calculated  creatinine 
clearance â‰¥ 60 mL /minute  
e. Aspartate aminotransferase (AST) â‰¤ 2.[ADDRESS_960762]; alanine ami notransferase (ALT) 
â‰¤2.[ADDRESS_960763];  AST/ALT < [ADDRESS_960764] if liver inv olvement  
f. Serum bilirubin â‰¤ 1.[ADDRESS_960765], except i n patients with Gilbertâ€™s Syndrome who 
must have a total bilirubin < 3 mg/dL  
IMO -2125   Page 12 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    7) Women of childbearing potential (WOCBP) and men must agree to use effective 
contraceptive methods from Screening throughout the study t reatment period and until at 
least [ADDRESS_960766] dose of pembrolizumab. 
Non-childbearing potential is defined as a woman  who meets either  of the following 
criteria: a) postmenopausal state defined as no menses for 12 months without an 
alternative medical cause, or b) documented hysterectomy, bilateral tubal ligation, or 
bilateral oophorectomy.  
Effective contraception methods are defined as one  of the following:  
a. True abstinence, defined as refraining from heterosexual intercourse, when this is 
in line with the preferred and usual lifestyle of the patient . Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of a trial, and withdrawal are not acceptable methods 
of contraception.  
b. Condoms and spermicide  
c. Diaphragm and spermicide  
d. Oral or implanted hormonal contraceptive (e .g., Implanonâ„¢)  
e. An intra -uterine device (IUD)  
8) WOCBP must have a negative pregnancy test (serum or  urine) prior to the first dose of 
study treatment.  
9) Patients must be willing and able to sign the informed consent and comply with the study 
protocol. 
10) Patients must have a n anticipated life expectancy >3 months. 
Exclusion criteria  
1) Patients who have received prior therapy with a TLR agonist , excluding topi[INVESTIGATOR_12450]. 
Patients who have received experimental vaccines or other investigational immune 
therapi[INVESTIGATOR_707143].  
2) Patients who have received systemic treatment with IFN -Î± within the previous 6 months 
prior to enrolling into this study . 
3) Patients with known hypersensitivity to any oligodeoxynucleotide . 
4) Patients with active autoimmune disease requ iring disease -modifying therapy . 
5) Patient s requiring concurrent systemic steroid therapy higher than physiologic dose  
(7.5 mg/day of prednisone) . 
6) Patients with any form of active primar y or secondary immunodeficiency . 
7) Patients with another primary malig nancy that has not been in remission for at least 
3 years. The following are exempt from the 3 year limit: non -melanoma skin cancer, 
curatively treated localized prostate cancer with non -detectable prostate- specific antigen, 
cervical carcinoma in situ on biopsy or a squamous intraepi[INVESTIGATOR_707144] 
(Pap)  smear, and thyroid cancer (except anaplastic).  
8) Patients with active systemic infections requiring antibiotics  or active hepatitis A, B, 
or C. 
IMO -2125   Page 13 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    9) Patient s who are hepatitis B surface antigen posi tive. 
10) Patients with a known diagnosis of human immunodeficiency virus (HIV) infection . 
11) WOCBP who  are pregnant or breast -feeding . 
12) Patients who have had prior anaphylactic or other severe infusion reaction associated 
with human antibody administration.  
13) Patie nts with known central nervous system, meningeal, or epi[INVESTIGATOR_707145]. Patients with 
stable brain metastases following definitive local treatment are eligible if steroid 
requirement is less than 7.5 mg/day of prednisone (or equivalent).  
14) Patients with impaired cardiac function or clinically significant cardiac disease such as:  
a. [LOCATION_001] Heart Association Class III or IV cardiac disease, including preexisting 
clinically significant ventricular arrhythmia, congestive heart failure , or 
cardiomyopathy  
b. Unstable an gina pectoris â‰¤6 months prior to study participation 
c. Acute myocardial infarction â‰¤ 6 months prior to study participation 
d. Other clinically significant heart disease (i.e., Grade â‰¥ 3 hypertension, history of 
labile hypertension, or poor compliance with an anti-hypertensive regimen ) 
15) Ocular melanoma.  
Investigational product, dosage, and mode of administration:  
In Phase 1, the starting dose of IMO -2125 will be 4 mg  (Dose Level +1) for the ipi[INVESTIGATOR_707146], and 8 mg (Dose Level +2) for the pembrolizumab combination (with de -escalation 
to 2 mg allowed  for each combination) . IMO -[ADDRESS_960767].   
IMO -2125 will be administered by [CONTACT_707236][INVESTIGATOR_707147] . 
Administration of ipi[INVESTIGATOR_707148] -2125 when administered in  
the same week ; IMO -[ADDRESS_960768] occur on the scheduled dosing day ( Â±2 day window). 
Note that tumor biopsies should be done prior to stud y treatment administration.  If a full dose 
can no longer be practically administered into the designated tumor for injection, another tumor 
may be selected.  In the event that complete tumor regression occurs in all accessible lesions prior 
to completion of  therapy, any remaining IMO -2125 doses should be administered into the tumor 
bed, except in the case of visceral lesions where remaining doses should be given s.c. to 
minimize procedural risks.  
Dose escalation:  Up to five dose levels for IMO -2125 are init ially planned (as shown in the table 
below ).  
Dose Level  IMO -2125  Ipi[INVESTIGATOR_707149]  
-1 2 mg  3 mg/kg  200 mg  
+1 4 mg  3 mg/kg  200 mg  
+2 8 mg  3 mg/kg  200 mg  
+3 16 mg  3 mg/kg  200 mg  
+4 32 mg  3 mg/kg  200 mg  
 
IMO -2125   Page 14 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    In Phase 1, t he study will enroll patients in planned cohorts of 3, beginning at Dose Level +1 for 
the ipi[INVESTIGATOR_707150] +2 for  the pembrolizumab  treatment 
arm once safety of the IMO -2125 + ipi[INVESTIGATOR_707151]. 
A charter will be used to guide the CRCâ€™s decision -making.  
Additionally, if, due to observed toxicity, it proves difficult to provide IMO -[ADDRESS_960769] treatment cycle of 
each cohort. Using a prior beta(1,1) distribution of the DLT rate Î´ i for each dose level i, th e 
MTD is defined as the highest dose level  for which the  mean of the  posterior distribution  of 
toxicity is closest to but less than 25% among all the evaluated doses i  for which 
Pr (Î´ i > 0.25 | data)  <0.80. 
The RP2D(s) will be selected from dose  level (s) at or below the MTD. Additional dose levels  
may be studied if the MTD(s) have not been reached and pharmacodynamic activity is deemed to  
be inadequate. At the time of  completion of the Phase 1 portion of the study , an analysis of the 
data will be performed .  
Assuming a prior beta (0.6, 1.4)  distribution for the overall toxicity rate for a treatment, a Phase 2 
arm will terminate if the Pr (Î´ t > 0.25 | data) >0.80, where Î´ t is the DLT rat e attributable to the 
treatment . 
Dose -limiting toxicities:  Toxicity will be evaluated according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) v4.03 toxicity criteria.  
Dose -limiting toxicities are defined in Section  8.1.5 and should be referenced throughout the 
Phase 1 and 2 portions of the study. The DLT evaluati on period will be Cycle 1 (Weeks 1 
through 4) .  
For the purpose s of dose level escalation and determination of the MTD (s), only DLTs (as 
defined below) that occur during the first cycle of treatment will be considered in the decisions 
regarding dose level escalation ; however, DLTs or other clinically significant toxicities that 
occur throughout the observation period will be  considered when determining the RP2D(s) for 
use in this trial and in subsequent clinical trials . 
During Cycle 1  of the dose escalation portion, if two  of the three patients  in a cohort  experience 
the same Grade 2, treatment- related AE , then subsequent increases in dose  level  will proceed in 
increments less than 100% . If more than one  cohort is treated at the same d ose level and greater 
than 67% of patients treated at that dose level experience the same Grade 2 t reatment -related AE, 
dose level escalation will proceed in increments less than  100%  (see table of planned dose level 
escalation above).  In such a case, s pecific dose level increments will be decided by [CONTACT_10186].  
Protocol -defined hematologic DLTs include:  
â€¢ CTCAE Grade 4 neutropenia â‰¥ 7 days ; 
â€¢ CTCAE Grade 3 or 4 neutropenia with fever â‰¥ 38.5Â°C;  
â€¢ CTCAE Grade 3 thrombocytopenia with bleeding;  
â€¢ CTCAE Grade 4 thrombocytopenia  â‰¥7 days . 
IMO -2125   Page 15 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Protocol -defined non -hematologic DLTs include:  
â€¢ Grade â‰¥ 3 vomiting or nausea â‰¥  14 days despi[INVESTIGATOR_58348]- emetic 
treatments ; 
â€¢ Grade â‰¥ 3 diarrhea â‰¥ 14 days despi[INVESTIGATOR_58348] -diarrheal treatments  which 
should i nclude infliximab  as per institutional guidelines ; 
â€¢ Serum creatinine > 3.[ADDRESS_960770] ; 
â€¢ AST or ALT >[ADDRESS_960771];  in patients with liver metastasis who entered the study with 
Grade [ADDRESS_960772] or ALT increase â‰¥ 50% relative to baseline 
and lasting  â‰¥1 week;  
â€¢ Bilirubin â‰¥3.[ADDRESS_960773] ; 
â€¢ Bilirubin â‰¥ 2.[ADDRESS_960774] with ALT >[ADDRESS_960775] in patients without liver metastases ; 
â€¢ Other non- hematologic toxicities of Grade  â‰¥3, except for the following:  
o AEs related to underlying disease ; 
o CTCAE Grade 3 fatigue <14 days ; 
o Alopecia;  
o Isolated, asymptomatic elevations in biochemis try laboratory values lasting 
â‰¤14 days. This includes electrolyte abnormalities that respond to medical 
intervention. 
Ipi[INVESTIGATOR_125] -related DLTs:  
â€¢ Grade â‰¥ 4 immune -mediated dermatitis (except skin reaction at site  of injection) ; 
â€¢ Grade â‰¥ 3 immune -mediated endocrinopathy (with the exception of Grade 3 autoimmune 
thyroiditis that resolves to Grade 1 or baseline within 28 days of onset) ; 
â€¢ Grade â‰¥ 3 immune -mediated enterocolitis ; 
â€¢ Grade â‰¥ 3 immune -mediated hepatitis with the  exception of Grade 3 immune -mediated 
hepatit is that resolves to Grade 1 or baseline within 28 days of onset ; 
â€¢ Grade â‰¥ 3 immune -mediated neuropathy, pancreatitis, meningitis, nephritis, and 
pneumonitis that are considered to be possibly, probably, or definit ely related to study 
therapy as determined by [CONTACT_737] ; 
â€¢ Any persistent IMO -2125- related toxicity that leads to a delay of scheduled (per  
standard of care) ipi[INVESTIGATOR_125] > 14 days . 
Pembrolizumab -related DLTs:  
â€¢ Grade â‰¥ 3 pneumonitis or recurrent Grade 2 pn eumonitis ;  
â€¢ Grade â‰¥ 3 nephritis ;  
â€¢ Grade â‰¥ 3 infusion- related reactions ;  
â€¢ Inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per 
day within 12 weeks ; 
â€¢ Any Grade â‰¥ [ADDRESS_960776] be assessed for attribution based on the known toxicity profiles for ipi[INVESTIGATOR_125], 
pembrolizumab,  and IMO -2125 . If assessment can be clearly attributed to one of the drugs in  the 
IMO -2125   Page 16 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    combination , then dosing should be interrupted and the toxicity should be followed until 
resolution, stabilization, or return to baseline. Treatment with the other agent may continue 
during this time period. If attribution cannot be clearly ascribed t o one agent versus the other, 
then both IMO -2125 and ipi[INVESTIGATOR_125] (or pembrolizumab) should be stopped and the toxicity 
should be followed until resolution, stabilization, or return to baseline. If treatment is to be 
resumed, then re -initiation criteria must be met. If the DLT was clearly related to IMO -[ADDRESS_960777] be administered at a lower dose  
level  (a minimum reduction of at least one  dose level). If the DLT recurs after a dose level 
reduction, t hen treatment should be discontinued.  
Patients who experience a non -laboratory, IMO -2125- related DLT must be evaluated weekly, at  
a minimum, until resolution to  Grade â‰¤ [ADDRESS_960778]. For abnormal laboratory values that 
qualify as DLTs, patients will be followed twice weekly until values return to Grade â‰¤ [ADDRESS_960779].  
Criteria for re -initiation of study treatment following occurren ce of a DLT are as follows:  
â€¢ ANC must be â‰¥ 1.5 x 109/L (1500/Î¼L) ; 
â€¢ Platelets must be â‰¥ 75 x 109/L (75,000/Î¼L) ; 
â€¢ All clinically significant non -hematologic toxicities for which a causal association to 
study treatment cannot be ruled out must be  Grade â‰¤ 1 (except alopecia) or returned to 
baseline.  
If the patient does not meet these criteria, dosing will be delayed and the patient should be 
re-evaluated within 48 to 72 hours. If the next cycle is delayed by [CONTACT_726] 21 days  for toxicity , 
the patient should be removed from study treatment. In these situations, if the patient is 
experiencing clinical benefit and has a favorable risk/benefit profile, study treatment with 
IMO -2125 may be continued if agreed upon by [CONTACT_66229]. 
Duration of study : The study treatment period is 29 weeks  in the absence of intolerable toxicity 
or unequivocal disease progression. Continued treatment with pembrolizumab following the  
completion of  IMO -2125  study treatment is at the discretion of the Investigator  for patients in the 
IMO -2125 + pembrolizumab treatment arm.  
The study ends approximately  [ADDRESS_960780] v1.1 
progressive disease (PD), start of a subsequent anti -cancer treatment regimen, withdrawal of 
consent, death, or Sponsor notification that follow -up is no longer required, whichever comes 
first. Best response to first subsequent therapy, AEs which are Grade â‰¥ 3, and concomitant 
medications used to treat these AEs, will also be captured during the follow -up phase of the 
study.  
After documentation of PD or use of a subsequent anti -cancer treatment regimen,  all patients will 
be contact[INVESTIGATOR_530] b y telephone every 3 months for  survival follow -up until  the site is  notified by [CONTACT_707237] -up is no longer required.  
IMO -2125   Page 17 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Assessments  
Safety: Safety assessments will include a comprehensive evaluation of AEs and/or toxicity based 
on: 
â€¢ Results of monitoring vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and body 
temperature) ; 
â€¢ Results of clinical chemistry, h ematology/coagulation, complement testing, thyroid 
function testing, and urinalysis  tests ; 
â€¢ ECG  results;  
â€¢ Changes in physical examination ; 
â€¢ Need for concomitant medications ; 
â€¢ ECOG performance status . 
Hematology assessment will inc lude a complete blood count  (CBC)  with a differential and a 
coagulation profile  will include prothrombin time  (PT) and activated partial thromboplastin 
time (aPTT) . The clinical chemistry panel will include the liver function tests  (AST, ALT, and 
serum bilirubin ), blood urea nitrogen, complement (total hemolytic complement activity 50 
[CH50 ], and complement components C3 and C4 ), and serum creatinine. The urinalysis will 
include urinary protein. 
Pharmacokinetics:  The plasma PK of single -dose IMO -2125 and the PK of repeat -dose 
IMO -2125 administered  by [CONTACT_707238][INVESTIGATOR_707152]. The following parameters will be 
determined for IMO -2125 plasma PK , if appropriate : 
â€¢ Maximum plasma concentration (C max); 
â€¢ Time of C max (tmax); 
â€¢ Area under the curve from [ADDRESS_960781] measurable plasma concentration (AUC 0-t). 
Serum concentrations of ipi[INVESTIGATOR_707153] 2, 5, 8, 11, 
17, and 23. For patients who continue pembrolizumab treatment, pembrolizumab pre -dose PK 
samples should be collected before dosing at all visits. A post -dose pembrolizumab PK sample 
should be collected 30 minutes after the initiation of pembrolizumab infusion at Week  23 (if 
administered) . 
Efficacy:  Efficacy will be evaluated by [CONTACT_707239] . Treatment 
decisions should be based on patient benefit as assessed by [CONTACT_707240] [ADDRESS_960782] v 1.1.  
Exploratory:  Exploratory variables will be assessed at pre -treatment and post -treatment and 
may include , but are not limited to:  
â€¢ PRO : Period ic assessments will be made using the EORTC -QTQ- C30 
â€¢ Biomarkers (CD8+ T  cells, natural killer cells, pDC/myeloid DC, memory T  cells in 
tumor tissue, T  cells, and cytokine levels in blood)  
â€¢ Any potential association between these biomarkers and antitumor activity  
IMO -2125   Page 18 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    â€¢ Gene profili ng (with ribonucleic acid [RNA]  and deoxyribonucleic [DNA] extraction)  
â€¢ Immunogenicity (antibodies to IMO -2125, ipi[INVESTIGATOR_125], and pembrolizumab)  
For Phase 1, biopsies of the injected tumor will be performed at the Screening Visit (within 
[ADDRESS_960783] treatment); within 24 to 48 hours after IMO -2125 injection on Week 1 
(Cycle  1); Week 2 ( Cycle 1; optional) ; during Week 8 (Cycle 3) ; and optionally  at Week  13 
(Cycle 4) and  at the time of disease progression or during Week 23, whichever is later . Tumor 
biopsies of the designated non- injected lesion will be performed at Screening , prior to the first 
dose of ipi[INVESTIGATOR_707154] (optional), and during Week 8. For Phase 2, tumor 
biopsies are optional at all specified visits. Surgical methods (e.g., punch or core) are preferred 
over Fine Needle Aspi[INVESTIGATOR_477104].  
Biopsies should be done prior to study treatment administration. For those patients who have 
liver or other visceral metastases injected with IMO -2125, repeat biopsy of liver or other visceral 
tumor lesions may not always be possible. Therefore, repeat biopsies will be performed only 
when feasi ble in these patients.  
The Week 8 (Cycle 3) and Week 13 (Cycle 4) biopsies may be performed within a Â±3  day 
window. If tumor response is observed early during initial treatment, the Week 8 biops ies may 
be performed at an earlier time point so as to ensure meaningful biomarker information is 
obtained prior to complete resolution of tumor.  
Statistical methods: Continuous variables will be summarized using descriptive statistics such 
as mean, standard deviation, median, and range. Categorical  variables will b e summarized by 
[CONTACT_707241], and if specified, with 95% confidence intervals for the proportion. Missing 
data will not be imputed  except as described in the Statistical Analysis Plan . 
Data will be analyzed at the end of dose -finding for each treatment . Phase 2 data will be 
analyzed at the end of Phase 2 ( approximately  [ADDRESS_960784] patient in Phase 2 has 
commenced study treatment ). 
Efficacy populations will include : 
â€¢ Primary Ipi[INVESTIGATOR_125] + IMO -2125 Effica cy Evaluable (PI[INVESTIGATOR_707155]) Population: all patients 
who are ipi[INVESTIGATOR_125] -naÃ¯ve on study entry  (including those who received ipi[INVESTIGATOR_707156]);  and who are treated at the RP2D for the IMO -2125 + ipi[INVESTIGATOR_707146], regardless of which phase of the study they receive it; and who received at 
least one dose of each study drug.  
â€¢ Secondary Ipi[INVESTIGATOR_125] + IMO -2125 Efficacy Evaluable (SIIEE) Population: all patients 
who are not ipi[INVESTIGATOR_125] -naÃ¯ve on study entry ; and who are treated at the RP2D for the 
IMO -2125 + ipi[INVESTIGATOR_707157] n, regardless of which phase of the study they 
receive it ; and who received at least one dose of each study drug.  
â€¢ Primary Pembrolizumab + IMO -2125 Efficacy Evaluable (PPI[CONTACT_232200]) Population: all 
patients  who are treated at t he RP2D for the IMO -2125 + p embrolizumab combination, 
regardless of which phase of the study they receive it; and who received at least one dose 
of each study drug . 
â€¢ Safety Population: all patients who received at least one dose of IMO -2125 . 
â€¢ DLT Evaluable Population: all patients in t he Safety Population who continue 
IMO -2125   Page 19 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    participation in the study for the entire DLT evaluation period, or who discontinue 
prematurely due to a DLT.  
â€¢ PK Population: All subjects in the Safety Population who have â‰¥[ADDRESS_960785] with Î± = 0.[ADDRESS_960786] 95% confidence 
intervals.  DCR will also be summarized by [CONTACT_393]  v1.1. 
The OS and  PFS proportions w ill be estimated  at 6 and 12 months; OS and PFS will also b e 
analyzed overall.  For time -to-event endpoints (OS, PFS, and DoR), the Kaplan- Meier method 
will be used to estimate the probability of event- free survival . Patients who have not experienced 
the ev ent at the data cut -off date for study closure  will be censored . Patients who are lost to 
follow up will be censored at the last valid disease assessment for PFS and date of last contact 
[CONTACT_707242] . Kaplan -Meier plots will be produced for OS and PFS by [CONTACT_273920] . 
Analysis of Exploratory Endpoints  
Patterns of missing data will be described for PRO. Mean change from Baseline in the global 
health status score over time will be summarized and presented graphically. A mixed model for 
repeated measures may be used to assess the statistical significance of changes from Baseline. 
Exploratory endpoint analyses will be fully described in the statistical analysis plan.  
Determination of Sample Size  
The primary objective of Phase 2 is to assess the preliminary clinical activity , defined as the 
investigator -assessed ORR, of IMO -2125 in combination with ipi[INVESTIGATOR_707158] -2125 in 
combination with  pembrolizumab in patients with progression on or following PD -(L)1 inhibitor 
therapy for metastatic melanoma. Given that two p rimary hypotheses are being tested ( regarding 
the ORR of IMO -2125 and ipi[INVESTIGATOR_707159] -2125 and pembr olizumab), a 
Bonferroni correction has been applied to the alpha to control the  Type I error  rate for the trial . 
Assuming the ORR for patients  who receive ipi[INVESTIGATOR_707160] 11% (the historical 
response rate in patients who are PD -1 inhibitor  naÃ¯ve), and a target  ORR of 35% for patients 
who re ceive IMO -2125 + ipi[INVESTIGATOR_707161], a sample size of 21 patients would 
achieve 77 % power to detect a 24% difference in response rates using a one -sided significance 
level of 2.5%.  
The IMO -2125 + ipi[INVESTIGATOR_707162] a two -stage design with a targeted Type I 
error rate of 0.[ADDRESS_960787] 35% . 
With this method, [ADDRESS_960788] v1.1 response in Stage 1, then the 
IMO -2125   Page 20 of 106 
Protocol 2125- 204, Version 8.0  Date: [ADDRESS_960789]  v1.1 response, then the null hypothesis H o will be rejected in 
favor of the alternative H a. In this treatment arm, this design has statistical power of 77%, an 
expected sample size of 13.[ADDRESS_960790] stage of 69.7% if the response proportion is â‰¤0.11.  
Assuming a RECIST v1.[ADDRESS_960791] 5%, and a target ORR of 35% for patients who receive IMO -2125 
+ pembrolizumab combination treatment, a sample size of 21 efficacy -evaluable patients would 
achieve 96% power to detect a 30% difference in response rates using a one -sided significance 
level of 2.5%.  
The IMO -2125 + pembrolizumab treatment arm will use a two -stage design with a targeted 
Type  I error rate of 0.[ADDRESS_960792] 35% . If at 
least [ADDRESS_960793] v1.1 
response, then the  null hypothesis H o will be rejected in favor of the alternative H a. In this 
treatment arm, this design has statistical power of 96%, an expected sample size of 14.41, and a 
probability of stoppi[INVESTIGATOR_707163] 60% if the response proportion is â‰¤0.05. 
Analysis of PK  
For each cohort, the plas ma IMO -2125 concentration data will be analyzed by 
[CONTACT_105]-compartmental PK analysis . Descriptive statistics will be provided for concentration data 
and all PK assessment values by [CONTACT_5349] (IMO -2125, i pi[INVESTIGATOR_125], and pembrolizumab), dose, 
and time, as appropriate.  
Dose proportionality using the power model will be evaluated in an exploratory manner, if the 
data permit. If insufficient data are available to assess dose proportionality using the power 
mode l, dose normalized data will be presented for a graphical assessment.  
The potential effects of IMO -2125 on the PK of ipi[INVESTIGATOR_707164].  
Date of Synopsis:  27 March 2018  
 
IMO -2125   Page 21 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Table  1: Phase 1: Schedule of Evaluations  
  Treatment Period (Cycle  1) Follow -up 
  1 2 3 4 5 6 7 Safety  2 Ongoing 3 
(every 3  months)   
Week 4 Screen 5 1 2 3 5 8 11 13 14 17 20 23 26 29/ 
EOT  32  
Informed consent  X                
Inclusion/Exclusion  X                
Demogr/med hx 6 X                
Adverse events  Continuous  X 7 
Concomitant Meds   Continuous  X 8 
ECOG  X X   X X X   X  X  X X  
CBC with diff X X X X X X X   X  X  X X  
Coagulation 9 X X 10   X X X   X  X  X X  
Chemistry profile  X X 10 X X X X X   X  X  X X  
Thyroid functions  X  X  X X X   X  X  X X  
CH50/C3/C4  X    X X X   X  X  X X  
Urinalysis  X     X    X     X  
Vital signs [ADDRESS_960794]  X              X  
Tumor 
biopsies/biomarkers 14, 
19 X X 15 X 16   X  X 16    X 16     
Blood biomarkers 19  X 17 X 17  X18 X18        X 18   
Radiology  X     X 20    X 20    X 20  X 21 
Response 22      X 20    X 20    X 20  X 21 
PRO  23  X    X    X    X  X 21 
IMO -2125 dosing   X X X X X X   X  X  X   
Ipi[INVESTIGATOR_45770]    X  X X X          
Pembrolizumab dosing    X  X X X  X 24 X 24 X 24 X 24 X 24 X 24 X 24 X 24 
PK testing 25  X X X X X X  X 26 X 26 X 26 X 26 X 26 X 26 X26  
Immunogenicity 27  X   X  X   X  X  X X X28 
IMO -2125   Page 22 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Abbreviations: AE=adverse event; aPTT=activated partial thromboplastin time; C3=complement component 3; C4=complement component 4; CBC=complete 
blood count; CH50=total hemolytic complement activity 50; CR=complete response; Demogr=Demographic; diff=differential; ECG=electrocardiogram; 
ECOG=Eastern Cooperative Oncology Group; EOT= End of Treatment; hx=history; INR=international normalized ratio; irRC=immune -related response 
criteria; med=medical; PK=pharmacokinetic; PR=partial response; PRO=patient reported outcomes; PT=prothrombin time ; RECIST=Response Evaluation 
Criteria in Solid Tumors  
[ADDRESS_960795] dose of IMO -2125 (Â± 5 days).  
3 Includes ongoing follow -up every 3 months until  documented disease progression, next mela noma treatment , withdrawal of consent, death, or Sponsor 
notification that follow -up is no longer required.  
4 All assessments and IMO -2125 dosing will occur within a Â± 2-day window. Ipi[INVESTIGATOR_707165].  
[ADDRESS_960796] be performed within 21 days of the start of Week 1 of Cycle 1, unless otherwise noted. Al l patients who sign an 
informed consent and are screened and qualify for the study will be considered enrolled.  
6 Including melanoma history  and prior melanoma treatment history . 
7 Grade â‰¤ 2 AEs do not need to be reported.  
8 Only concomitant medications for the treatment of Grade â‰¥[ADDRESS_960797] -IMO -2125 administration.  
13 Including assessment of melanoma lesions.  
14 Biopsy of the tumor to be injected wi th IMO -2125 and biopsy of a tumor that will not be injected. See Section  13.2 and the Laboratory Manual for details on 
the collection of biopsies and analys es of biomarkers.  
15 Biopsy of the injected tumor  should occur within 24 to 48 hours after injection (no more tha n 48 hours) . The blood biomarker samples will be collected on Day 
1 before IMO -2125 administration then 4 hours (serum for cytokines), and within 24 to 48 hours after the injection, and also pre -dose at the Cycle 1 Week 2 
Visit (serum for cytokines).  
16 Optional biopsy.  
17 The blood biomarker samples will be collected on Day 1 before IMO -2125 administration , then 4 hours (serum for cytokines), and within 24 to 48 hours after 
the injection, and also pre -dose at the Cycle 1 Week 2 Visit (serum for cytokines)  
[ADDRESS_960798] -dosing.  
19 Biopsies and blood biomarker samples will not be performed ex -US. 
20 Radiologic assessment and Investigator assessment of response at Week 8 , Week 17, and Week 29  may be conducted within a Â± 7-day window.  
[ADDRESS_960799] subsequent treatment should also be captured.  Confirmatory scans for CR, 
PR, and progressive disease  should be performed â‰¥ [ADDRESS_960800] documented.  
23 The PRO assessments should be completed before study drug administration and AE assessments.  
24 For patients assigned to the IMO -2125 + pembrolizumab treatment arm, continued pembrolizumab dosing per the approved product label is permitted at the 
discretion of the Investigator . 
IMO -2125   Page 23 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    25 PK: blood sampling for analysis of plasma concentrations of IMO -2125 and serum concentrations of  ipi[INVESTIGATOR_125], and pembrolizumab (See Table  3 for specific 
collection times).  
[ADDRESS_960801] -dose 
pembrolizumab PK sample should be collected 30 minutes after initiation  of pembrolizumab infusion at Week 23  and Week 32 . Pharmacokinetic samples at 
Week  32 are optional.  
27 Immunogenicity: blood sampling for analysis of ant ibodies to IMO -2125, ipi[INVESTIGATOR_125] , and pembrolizumab will be performed prior to any dosing at that visit.  
28 For patients in Ongoing Follow -up (i.e., those discontinued from study treatment before progression or new anticancer treatment), the immunogenicity samples 
are required at the scheduled visits. For patients in survival follow -up (i.e. , after progressive disease  or start of new anti -cancer treatment), immunogenicity 
assessments are optional  (e.g., if a patient comes to the investigator site for a Survival Follow -up Visit rather than the usual telephone contact).  
IMO -2125   Page 24 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Table  2: Phase 2 : Schedule of Evaluatio ns 
  Treatment Period (Cycle  1) Follow -up 
  1 2 3 4 5 6 7 Safety  2 Ongoing 3 
(every 3 months)   
Week 4 Screen 5 1 2 3 5 8 11 13 14 17 20 23 26 29/ 
EOT  32  
Informed consent  X                
Inclusion/Exclusion  X                
Demogr/med hx 6 X                
Adverse events  Continuous  X 7 
Concomitant Meds   Continuous  X 8 
ECOG  X X   X X X   X  X  X X  
CBC with diff X X X X X X X   X  X  X X  
Coagulation 9 X X 10   X X X   X  X  X X  
Chemistry profile  X X 10 X X X X X   X  X  X X  
Thyroid functions  X  X  X X X   X  X  X X  
CH50/C3/C4  X    X X X   X  X  X X  
Urinalysis  X     X    X     X  
Vital signs [ADDRESS_960802]  X              X  
Tumor 
biopsies/biomarkers 14, 17 X X 15 X   X  X    X     
Blood biomarkers 17  X 16 X 16   X16           
Radiology  X     X 18    X 18    X 18  X 19 
Response 20      X 18    X 18    X 18  X 19 
PRO  21  X    X    X    X  X 19 
IMO -2125 dosing   X X X X X X   X  X  X   
Ipi[INVESTIGATOR_45770]    X  X X X          
Pembrolizumab dosing    X  X X X  X 22 X 22 X 22 X 22 X 22 X 22 X 22 X 22 
PK testing 23  X X X X X X  X 24 X 24 X 24 X 24 X 24 X 24 X 24  
Immunogenicity 25  X   X  X   X  X  X X X26 
IMO -2125   Page 25 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Abbreviations: AE=adverse event; aPTT=activated partial thromboplastin time; C3=complement component 3; C4=complement component 4; CBC=complete 
blood count; CH50=total hemolytic complement activity 50; CR=complete response; Demogr=Demographic; diff=differential; ECG=electrocardiogram; 
ECOG=Eastern Cooperative Oncology Group; EOT= End of Treatment; hx=history; INR=international normalized ratio; irR ECIST=immune -related Response 
Criteria  in Solid Tumors ; med=medical; PK=pharmacokinetic; PR=partial response; PRO=patient reported outcomes; PT=prothrombin time ; 
RECIST=Response Evaluation Criteria in Solid Tumors; RP2D=recommended Phase [ADDRESS_960803] dose of IMO -2125 (Â± 5 days).  
3 Includes ongoing follow -up every 3 months until documented disease progression, next melanoma treatment, withdrawal of consent, death, or Sponsor 
notification that follow -up is no longer required.  
4 All assessments and IMO -2125 dosing will occur within a Â± 2-day window. Ipi[INVESTIGATOR_707166].  
[ADDRESS_960804] be performed within 21 days of the start of Week 1 of Cycle 1, unless  otherwise noted. All patients who sign an 
informed consent and are screened and qualify for the study will be considered enrolled.  
6 Including melanoma history and prior melanoma treatment history.  
7 Grade â‰¤2 AEs do not need to be reported.  
8 Only conco mitant medications for the treatment of Grade â‰¥ [ADDRESS_960805] -IMO -2125 administration.  
13 Including assessment of melanoma lesions.  
14 In Phase 2, all tumor b iopsies are optional.  See Section  13.2 and the Laboratory Manual for details on the collection of biopsies and analyses of biomarkers.  
15 Biopsy of the in jected tumor should occur within 24 to 48 hours after injection (no more tha n 48 hours) . The blood biomarker samples will be collected on Day 
1 before IMO -2125 administration then 4 hours (serum for cytokines), and within 24 to 48 hours after the injection, and also pre -dose at the Cycle 1 Week 2 
Visit (serum for cytokines).  
[ADDRESS_960806] 20 patients  treated at the IMO -2125 RP2D after which the Sponsor will determine if 
additional samples are needed. The blood biomarker samples will be collected on Day 1 before IMO -2125 admin istration , then 4 hours  (serum for cytokines) , 
and within 24 to 48 hours after the injection , and also pre -dose at the Cycle 1 Week 2 Visit  (serum for cytokines) and Cycle 3 Week 8 Visit.  
17 Biopsies and blood biomarker samples will not be performed ex -US. 
18 Radiologic assessment and Investigator assessment of response at Week 8, Week 17, and Week 29 may be conducted within a Â± 7-day window.  
[ADDRESS_960807] subsequent treatment should also be captured. Confirmatory scans for 
CR, PR, and progressive disease should be pe rformed â‰¥[ADDRESS_960808] documented.  
21 The PRO assessments should be completed before study drug administration and AE assessments.  
22 For patients assigned to the IMO -2125 + pembrolizumab treatment arm, continued pembrolizum ab dosing per the approved product label is permitted at the 
discretion of the Investigator.  
23 PK: blood sampling for analysis of plasma concentrations of IMO -2125 and serum concentrations of ipi[INVESTIGATOR_125], and pembrolizumab (See Table  3 for specific 
collection times).  For each combination i n Phase 2, the collection of plasma concentration samples will be done on at least 20 patients  treated at the IMO -2125 
RP2D  after which the Sponsor will determine if additional samples are needed.  
IMO -2125   Page 26 of 106 
Protocol 2125- 204, Version 8.0  Date: [ADDRESS_960809] -dose 
pembrolizumab PK sample should be collected 30 minutes after initiation  of pembrolizumab infusion at Week 23  and Week 32 . Pharmacokinetic samples at 
Week  32 are optional.  
25 Immunogenicity: blood sampling for analysis of antibodies to IMO -2125, ipi[INVESTIGATOR_125] , and pembrolizumab will be performed prior to any dosing at that visit.  
26 For patients in Ongoing Follow -up (i.e., those discontinued from study treatment before progression or new anticancer treatment), the immunogenicity samples  
are required at the scheduled visits. For patien ts in survival follow -up (i.e., after progressive disease or start of new anti -cancer treatment), immunogenicity 
assessments are optional (e.g. , if a patient comes to the investigator site for a Survival Follow -up Visit rather than the usual telephone cont act). 
IMO -2125   Page 27 of 106 
Protocol 2125- 204, Version 8.0  Date: 27 March  2018  
   
 Confidential   
    Table  3: Schedule of  PK Blood Sampling for IMO -2125, Ipi[INVESTIGATOR_125] , and  Pembrolizumab  
 Cycle 1  Cycle 
2 Cycle 
3 Cycle 4  Cycle 5  Cycle 6  Cycle 7  Safety 
Follow -up1 
 Week 
1 Week 
2 Week 
3 Week 
5 Week 
8 Week 
11 Week 
14 Week 
17 Week 
20 Week 
23 Week 
26 Week 29 
/EOT  Week [ADDRESS_960810]-dose             X2 
30 m (Â±5 m)  X     X      X  
1 h (Â±10 m)  X     X      X  
1.5 h (Â±10 m)  X     X      X  
3 h (Â±15 m)  X     X      X  
Ipi[INVESTIGATOR_707167]-dose  X  X X X  X [ADDRESS_960811]-dose             X2 
90 m after start 
of infusion 
(Â±5 m)   X    X        
Pembrolizumab               
Pre-dose  X  X X X X X X X X X X2 
Post-dose              
30 m after start 
of infusion 
(Â±5 m)   X    X    X   X2 
Abbreviations: EOT=End of Treatment; h=hour; m=minute; PK=pharmacokinetic  
1 Collection of PK samples at the Safety Follow -up Visit is optional.  
2 IMO -2125 (plasma samples) and ipi[INVESTIGATOR_125] (serum) PK samples may be collected at any time during the Safety Follow -up Visit. Optional pre - and post -dose 
pembrolizumab serum PK samples are collected for those patients continuing pembrolizumab treatment at th is visit. If pembrolizumab treatment was stopped, a 
sample may be collect ed at any time during the visit.  
3 Pre-IMO -2125 dose.  
 
 
 
IMO -2125  Page 28 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960812] OF ABBREVIATION S AND DEFINITIONS OF  TERMS .............................34  
4. BACKGROUND INFORMATI ON AND RATIONALE ..........................................38  
4.1. Metastatic Melanoma: The Disease Under Study  ......................................................[ADDRESS_960813] of Care Therapy  ..............................................................................38  
4.3. Toll-like Receptors and Their Agonists  ......................................................................39  
4.3.1.  Toll-like Receptor A gonists in the Treatment of Solid Tumors  .................................39  
4.4. IMO -2125  ...................................................................................................................40  
4.4.1.  Mechanism of Action  .................................................................................................40  
4.4.2.  Nonclinical Pharmacodynamics  .................................................................................40  
[IP_ADDRESS].  Studies in Models of Disease  ......................................................................................41  
4.5. Previous Human Experience  .......................................................................................41  
4.6. Rationale for Study Design and Selection of Dose  ....................................................41  
4.6.1.  Rationale for this Phase 1/2 Study  ..............................................................................42  
[IP_ADDRESS].  Rationale for Intratumoral Injection of IMO -2125  .....................................................42  
4.6.2.  Rationale for Population .............................................................................................42  
4.6.3.  Rationale for Design  ...................................................................................................43  
4.6.4.  IMO -2125 Starting Dose Rationale  ............................................................................43  
5. STUDY OBJECTIVES  ..............................................................................................44  
5.1. Primary Objective  .......................................................................................................44  
5.2. Secondary Objectives  .................................................................................................44  
5.3. Exploratory Objectives  ...............................................................................................44  
6. STUDY ENDPOINTS  ................................................................................................45  
6.1. Primary Endpoints  ......................................................................................................45  
6.2. Secondary Endpoints  ..................................................................................................45  
6.3. Exploratory Endpoints  ................................................................................................45  
7. PATIENTS TO BE RECRU ITED ..............................................................................46  
7.1. Patient Recruitment ....................................................................................................46  
IMO -2125  Page 29 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    7.2. Inclusion Criteria  ........................................................................................................46  
7.3. Exclusion Criteria  .......................................................................................................48  
8. STUDY DESIGN  .......................................................................................................49  
8.1. Overview  .....................................................................................................................49  
8.1.1.  Phase 1  ........................................................................................................................49  
8.1.2.  Phase 2  ........................................................................................................................50  
8.1.3.  Dose Escalation and Stoppi[INVESTIGATOR_1869]  ..........................................................................51  
[IP_ADDRESS].  Phase 2 Stoppi[INVESTIGATOR_1869]  ..............................................................................................51  
8.1.4.  Cohort Review Committee  .........................................................................................52  
8.1.5.  Definition of Dose -limiting Toxicities  .......................................................................52  
8.1.6.  Safety Assessment for Immunologically Related Toxicity  ........................................54  
8.2. Duration of Study  .......................................................................................................55  
8.2.1.  Treatment Duration  .....................................................................................................55  
8.2.2.  Study Duration  ............................................................................................................55  
8.3. Number of Patients  .....................................................................................................55  
8.4. Benefits and Risk Assessment  ....................................................................................55  
9. STUDY PROCEDURES BY [CONTACT_16990]  ..........................................................................56  
9.1. Screening (Up to 21 Days Before Day 1 of Week 1, Cycle 1)  ...................................56  
9.2. Cycle 1 Dosing Days (Weeks 1, 2, and 3)  ..................................................................[ADDRESS_960814] intratumoral IMO -2125 Injection .......................................................................57  
9.3. Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, and Cycle 7 Dosing Days 
(Weeks 5, 8, 11, 17, 23, and 29)  .................................................................................[ADDRESS_960815]-dose .....................................................................................................................59  
9.4. Cycle 4 (Week 13)  ......................................................................................................59  
9.5. Safety Follow -up Visit ([ADDRESS_960816] Dose of IMO -2125)  ...............................59  
9.6. Early Withdrawal  ........................................................................................................60  
9.7. Unscheduled Visits  .....................................................................................................60  
10. STUDY TREATMENTS ............................................................................................61  
10.1.  IMO -2125  ...................................................................................................................61  
IMO -2125  Page 30 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    10.2.  Ipi[INVESTIGATOR_125]  ..................................................................................................................61  
10.3.  Pembrolizumab  ...........................................................................................................61  
10.4.  Drug Handling and Administration ............................................................................61  
10.4.1.  Drug Delivery to Site  ..................................................................................................61  
10.4.2.  Drug Storage  ...............................................................................................................61  
[IP_ADDRESS].  IMO -2125 Storage  ......................................................................................................61  
[IP_ADDRESS].  Ipi[INVESTIGATOR_665262]  ....................................................................................................62  
[IP_ADDRESS].  Pembrolizumab Storage  ..............................................................................................62  
10.4.3.  Administration  ............................................................................................................62  
[IP_ADDRESS].  IMO -2125  ...................................................................................................................62  
[IP_ADDRESS].  Ipi[INVESTIGATOR_125]  ..................................................................................................................62  
[IP_ADDRESS].  Dose Interruption for Ipi[INVESTIGATOR_125]- Related Toxicities  ................................................63  
[IP_ADDRESS].  Pembrolizumab  ...........................................................................................................64  
[IP_ADDRESS].  Dose Interruption for Pembrolizumab- Related Toxicities  .........................................64  
[IP_ADDRESS].  Supportive Care Guidelines for Hypophysitis  ............................................................65  
10.5.  Labeling  ......................................................................................................................65  
10.6.  Drug Accountability  ...................................................................................................65  
10.6.1.  IMO -2125 Dose Reduction .........................................................................................65  
10.6.2.  Discontinuation of Study Drug ...................................................................................66  
10.7.  Concomitant and Prohibited Medications  ..................................................................66  
10.7.1.  Concomitant Medications  ...........................................................................................66  
10.7.2.  Prohibited Medications  ...............................................................................................66  
11. ADVERSE EVENT REPORT ING ............................................................................67  
11.1.  Adverse Events  ...........................................................................................................67  
11.1.1.  Definition of Adverse Events  .....................................................................................67  
[IP_ADDRESS].  Adverse Event  .............................................................................................................67  
[IP_ADDRESS].  Serious Adverse Event  ................................................................................................67  
[IP_ADDRESS].  Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  .....................................68  
11.1.2.  Recording Adverse Events  .........................................................................................68  
11.1.3.  Characterizing Adverse Events  ...................................................................................68  
[IP_ADDRESS].  Description of Event  ...................................................................................................68  
[IP_ADDRESS].  Date and Time of Onset  ..............................................................................................69  
IMO -2125  Page 31 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS].  Relationship to Study Drug ........................................................................................69  
[IP_ADDRESS].  Immune -related Adverse Events  .................................................................................70  
[IP_ADDRESS].  Severity  .......................................................................................................................70  
[IP_ADDRESS].  Grading of Laboratory Safety Tests for Reporting and Analysis  ...............................71  
[IP_ADDRESS].  Management of Study Drug upon Occurrence of an Adverse Event  .........................71  
[IP_ADDRESS].  Actions Taken for Management of Adverse Event  ....................................................71  
[IP_ADDRESS].  Follow -up and Outcome of Adverse Events  ...............................................................71  
[IP_ADDRESS].  Date and Time of Outcome .........................................................................................72  
11.1.4.  Reporting Adverse Events  ..........................................................................................72  
[IP_ADDRESS].  Where to Report Serious Adverse Events  ..................................................................72  
[IP_ADDRESS].  Procedures for Reporting Serious Adverse Events to the Sponsor  .............................73  
[IP_ADDRESS].  Other Reportable Events  .............................................................................................73  
[IP_ADDRESS].  Requirements for Expedited and Periodic Reporting of Adverse Events  ...................74  
12. SAFETY ASSESSMENTS  ........................................................................................75  
12.1.  Vital Signs  ..................................................................................................................75  
12.2.  Laboratory Assessments  .............................................................................................75  
12.3.  Other Safety Assessments  ...........................................................................................76  
12.3.1.  Physical Examination  .................................................................................................76  
12.3.2.  Electrocardiogram Monitoring ...................................................................................77  
12.3.3.  ECOG Performance Status  .........................................................................................77  
13. PHARMACOKINETICS AND IMMUNE RESPONSE  ...........................................78  
13.1.  Pharmacokinetic Assessments  ....................................................................................78  
13.2.  Pharmacodynamic Markers of Immune Response  .....................................................78  
13.2.1.  Immunogenicity Analyses  ..........................................................................................79  
13.2.2.  Immunologic Evaluations  ...........................................................................................79  
14. ASSESSMENT OF EFFICA CY ................................................................................80  
14.1.  Tumor Response  .........................................................................................................80  
15. ASSESSMENT OF PATIEN T REPORTED OUTCOMES  ......................................81  
15.1.  EORTC QLQ -C30 ......................................................................................................81  
16. STATISTICAL ANALYSIS  METHODS  ..................................................................82  
16.1.  Determination of Sample Size  ....................................................................................82  
16.2.  Analysis Populations  ..................................................................................................83  
IMO -2125  Page 32 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960817] Retention  .....................................................................89  
18.10.  Study Closeout  ............................................................................................................89  
18.11.  Audit/Inspections  ........................................................................................................90  
19. ETHICAL CONSIDERATIONS ................................................................................91  
19.1.  Role of Sponsor  ..........................................................................................................91  
19.2.  Informed Consent  .......................................................................................................91  
19.3.  Confidentiality of Patients  ..........................................................................................92  
19.4.  Authorization for Use and Disclosure of Protected Health Information ....................92  
19.5.  Human Patient Protections  .........................................................................................93  
19.5.1.  Research Patient Selection and Justification of Exclusio ns .......................................93  
19.5.2.  Risks/Discomforts of Study Participation  ..................................................................93  
19.6.  Institutional and Ethics Review  ..................................................................................94  
19.7.  Financial Disclosure  ...................................................................................................94  
IMO -2125  Page 33 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960818] OF REFERENCES  ............................................................................................95  
21. APPENDICES  ............................................................................................................99  
21.1.  Eastern Cooperative Oncology Group  ........................................................................99  
21.2.  Immune -Related Response Criteria (irRC)  ..............................................................[ADDRESS_960819] (Immune -Related Response Evaluation Criteria in Solid Tumors)  .........[ADDRESS_960820] OF TABLES  
Table 1:  Phase 1: Schedule of Evaluations  ...............................................................................21  
Table 2:  Phase 2: Schedule of Evaluations  ...............................................................................24  
Table 3:  Schedule of PK Blood Sampling for IMO -2125, Ipi[INVESTIGATOR_125], and 
Pembrolizumab  ...........................................................................................................27  
Table 4:  Schedule of Dosing for Phase 1 and Phase 2  ..............................................................49  
Table 5:  Treatment Doses to be Investigated  ............................................................................51  
Table 6:  Phase 2 Stoppi[INVESTIGATOR_274353]  .....................................................................................51  
Table 7:  Estimating Severity Grade  ..........................................................................................70  
Table 8:  Date and Time of Outcome for Adverse Event by [CONTACT_15987]  ............................72  
Table 9:  Laboratory Measurements  ..........................................................................................76  
Table 10:  ORR and Confidence Intervals with an ORR of At Least 0.35 for Possible 
Sample Sizes  ...............................................................................................................82  
 
 
IMO -2125  Page 34 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960821] measurable plasma concentration  
AUC 0â€“âˆž Area under curve from 0 to infinity  
C3/C4  Complement component 3/4 
CBC Complete blood count  
CFR Code of Federal Regulations  
CH50  Total hemolytic complement activity 50  
CpG  Unmethylated CG dinucleotides (cytosine- phosphate -guanine)  
CL/F  Clearance  
Cmax Maximum plasma concentration  
CPI [INVESTIGATOR_707168] -4 Cytotoxic T lymphocyte antigen- 4 
DCR  Disease control rate  
DLT  Dose -limiting toxicity  
DNA  Deoxyribonucleic acid  
DoR  Duration of response  
DRR  Durable response rate  
EC Ethics Committee  
ECG  Electrocardiogram  
IMO -2125  Page 35 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960822]  Immune -related Response Evaluation Criteria in Solid Tumors  
ISR Injection site reaction  
IUD intra-uterine device  
i.v. Intravenous(ly)  
LFT Liver function test  
mAb  Monoclonal antibody  
MCP  Monocyte chemoattractant protein  
MRT  Mean residence time 
MTD  Maximum tolerated dose  
NCI National Cancer Institute  
NFÎºB  Nuclear factor kappa -light- chain -enhancer of activated B cells  
NK Natural killer  
IMO -2125  Page 36 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Abbreviation  Definition  
ORR  Objective response rate  
OS Overall survival  
PAMP  Pathogen- associated molecular pattern  
Pap Papanicolaou  
PBMC Peripheral blood mononuclear cell  
PD Progressive disease  
PD-1 Programmed cell death -1 
pDC  Plasmacytoid dendritic cell  
PFS Progression- free survival  
PHI Protected health information 
PI [INVESTIGATOR_707169] + IMO -2125 Efficacy Evaluable  
PK Pharmacokinetic  
PPI[INVESTIGATOR_707170] + IMO -[ADDRESS_960823]  Response Evaluation Criteria in Solid Tumors  
RNA  Ribonucleic acid  
RP2D  Recommended Phase 2 dose  
SAE  Serious adverse event  
s.c. Subcutaneous(ly)  
SD Stable disease  
SFU Safety Follow -up 
SIIEE  Secondary Ipi[INVESTIGATOR_125] + IMO -2125 Efficacy Evaluable  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
t1/2 Terminal exponential half -life 
Th T helper  
IMO -2125  Page 37 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960824] insert  
Vd/F  Volume of distribution  
WBC White blood cell  
WOCBP  Women of childbearing potential  
IMO -2125  Page 38 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    4. BACKGROUND INFORMATI ON AND RATIONALE  
4.1. Metastatic Melanoma : The Disease Under Study  
Melanoma is a malignant tumor of melanocytes which are found predomi nantly in skin, but also 
in the mucous membranes  and eye. Melanoma causes the majorit y of skin cancer -related deaths . 
In 2014, 76,100 people in the US were newly diagnosed with either invasive or in situ melanoma 
and 9,710 cases were fatal. While the incid ence of many types of cancer has remained stable or 
declined, the incidence rates are increasing for melanoma and the probability of developi[INVESTIGATOR_707171] (Sie gel 2015).  
Although melanoma is a rare form of skin cancer, it comprises over 75% of skin cancer deaths. 
Patients with early (stage 1) lesions have 3 -year survival rates (>90%); however, patients with 
late-stage melanoma often have poor prognoses and survival rates (â‰¤10%) with a median 
survival of <8 months from time of diagnosis  (Lachiewicz  2008). 
Melanoma t reatment is dependent upon the stage of the cancer at the time of detection and the 
properties of the tumor . Tumors in early stages  can be removed surgically. However, i f a biopsy 
reveals that the cancer has metastasized and spread to lymph nodes, treatments are more likely to 
include  radiation and chemotherapy  regimens . While the goal of chemotherapy treatments is to 
induce apoptosis, or cell death , of the cancer cells , healthy noncancerous cells are often a ffected 
and are responsible for many of the adverse effects of systemic non -specific therapi[INVESTIGATOR_014].  A new 
approach to cancer therapy is immunotherapy; stimulation of the patientâ€™s own immune 
mechanisms that are responsible for naturally eliminating cancer cells.  
4.2. Current Standard of Care Therapy  
Melanoma that has metastasized is typi[INVESTIGATOR_707172]; surgery and radiation 
can be used in a palliative manner to treat sym ptoms of local tumor growth. Cy totoxic 
chemotherapi[INVESTIGATOR_014] (both alone and in combinations) have been used for more than 30 years and 
include alkylating  agents (dacarbazine, temoz olomide, and nitrosoureas), the platinum analogs, 
and the microtubular toxins (vinca alkaloids and toxanes) ( Bhatia  2009).  
In 1998, the Food and Drug Administration ( FDA)  approved the use of recombinant interleukin 
(IL)-2 to treat advanced melanoma ( Atkins, 1999; Atkins, 2000) and interferon (IFN )-Î± has also 
been used  as treatment either after surgery or in combination with other melanoma therapi[INVESTIGATOR_014]  
(Kirkwood, 2000) . More recently, check point inhibitors (CPIs) have emerged as a new 
immunology -based frontier to effect antitumor activity. Ipi[INVESTIGATOR_142] a monoclonal antibody 
(mAb) targeted to cytotoxic T lymphocyte antigen- 4 (CTLA -4). CTLA -4, present on CD4+ and 
CD8+ T lymphoc ytes is involved in maintaining a specific population of r egulatory T  cells and is 
a negative re gulator  of T cell activation ( Brunet 1987; Levings 2001). By [CONTACT_707243] -4, ipi[INVESTIGATOR_707173] T cell 
proliferation and activation (Walunas 1994) . Pembrolizumab and nivolumab are mA bs targeted 
to programmed cell death -1 (PD -1) (Shin and Ribas 2015) . The combination of ipi[INVESTIGATOR_707174]-PD-1 antibodies for the treatment of metastatic mela noma has demonstrated impressive 
antitumor activity, including 11.5 months median progression- free survival ( PFS; Larkin  2015)  
and 61%  objective response rate ( ORR; Postow  2015) , but with increased toxicity over 
IMO -2125  Page 39 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    single -agent therapy. An unmet need remains in this patient population for novel CPI 
[INVESTIGATOR_707175] 
(Zamarin and Postow  2015) .  
Intratumoral  administration of IMO -2125 is a logical complement to CPIs. Intratumoral 
IMO -2125 has been shown in nonclinical models to improve systemic antitumor immunity 
through stimulation of local antigen presentation, generation of cytotoxic T lymphocytes, and 
increasing the number and extent of tumor -infiltrating T cells , which is highly corre lated with the 
effectiveness of CPI [CONTACT_48831]  (Tumeh  2014) . 
4.3. Toll-like Receptors and Their Agonists  
The human innate immune system recognizes biochemical patterns that may be associated with 
pathogens (pathogen -associated molecular patterns, or PAMPs). Immune  system cells contain 
toll-like receptors ( TLRs ) that recognize PAMPs. Ten functional TLRs have been identified in 
humans. Some TLRs are expressed on the cell surface and recognize PAMPs such as 
lipopeptides, lipopolysaccharides, and flagellin. Other TLRs are expressed intracellularly on 
endosomal membranes and recognize single - and double -stranded ribonucleic acid ( RNA ; 
TLRs  3, 7, and 8) or deoxyribonucleic acid (DNA) containing unmethylated cytosine -guanine 
(CpG) dinucleotides (TLR9), which are patterns a ssociated with viruses or bacteria. The cellular 
distribution of TLRs also varies. TLR9 in humans is expressed only in plasmacytoid dendritic 
cells (pDCs) and B  cells, both of which are components of the peripheral blood mononuclear 
cells ( PBMCs) ([COMPANY_005] a nd Akira  2005; Wickelgren 2006). Activation of some TLRs causes 
signaling cascades that can promote cytokine production through the nuclear factor 
kappa -light-chain -enhancer of activated B cells (NFÎºB) or an IFN regulator factor mechanism 
(Abreu  2010).  
TLR 9 agonists induce pDCs to produce type I IFN and other cytokines and chemokines, which 
in turn activate other immune cells including T cells, monocytes, natural killer ( NK) cells, and 
macrophages (Liu, 2005). Agonists of TLR9 also induce activation, differ entiation, and 
proli feration of B  cells (Bernasconi  2002) . Together, the innate and adaptive immune responses 
generated through TLR9 produc e a profile of potentially anti tumor cytokines and chemokines, 
antigen -specific cytotoxic T lymphocytes, and enhanced antigen presentation capabilities  (Liu  
2005) .  
4.3.1. Toll-like Receptor A gonists in the Treatment of Solid T umors  
Human TLR7 and TLR9 are expressed primarily o n pDCs  ([COMPANY_005] and Akira 2005; Wickelgren 
2006) , which play a fundamental role in the regulation of the immune response during tumor 
development . Plasmacytoid DC s are present in high numbers within cutaneous melanoma and 
tumor -draining lymph nodes; however, the inf iltration of these cells is correlated with a poor 
clinical outcome.  Within the melanoma tumo r environment, pDCs were found to promote  a T 
helper (Th)  2-type response with a regulatory immune profile, promoting tumor progression 
(Aspord  2013) . In contra st, pDC activation via a TLR [ADDRESS_960825]  facilitates Th1 -type adaptive 
immune responses, including the generation of antigen -specific antibodies, cytotoxic T 
lymphocytes , and memory T  cells , all of which can lead to T  cell-mediated tumor destruction . 
IMO -2125  Page 40 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    4.4. IMO -2125 
4.4.1. Mechanism of Action  
Immune Modulatory Oligonucleotide -2125 ( IMO -2125) , a novel phosphorothioate  
oligodeoxynucleotide , is composed of 2 strands of modified D NA joined at their 3â€™ ends. 
IMO -2125 was created by [CONTACT_707244], Inc. through a structure activity approach to 
the design of TLR -targeted drug candidates based on modifications of class ical CpG DNA (Yu, 
2002; Kandimalla, 2003; Kandimalla, 2005). IMO -[ADDRESS_960826] spectrum of innate and adaptive 
immune responses, including antigen- specific cytotoxic T lym phocyte responses. IMO -2125 
stimulates pDCs and B cells through TLR9 to initiate a rapid innate immune response 
characterized by [CONTACT_707245] -1Î², IL -6, IL-12, IFN-Î³, 
interferon gamma -induced protein (IP) -10, tumor  necrosis factor (TNF) -Î±, monocyte 
chemoattractant protein -1 (MCP -1), and, particular to pDC  cells, high amounts of IFN -Î±. A 
secondary phase of the innate immune response is activation of NK cells, monocytes, and 
neutrophils and margination of lymphocytes out of systemic circulation. These hematological 
effects are evident consi stently at [ADDRESS_960827] -dose. T  cells are induced by [CONTACT_707246]/chemokine response into a Th1- type cellular response that includes production of 
cytotoxic T lymphocytes and antige n-specific memory T cells.   
4.4.2. Nonclinical Pharmacodynamics  
When IMO -2125 was subcutaneously ( s.c.) administer ed into cynomolgus monkeys, plasma 
concentrations of IFN -Î± began to increase early, peaking at approximately [ADDRESS_960828] 96 hours at a dosage of 4 mg/kg (Trombino 
2007a). Other signs of immune stimulation foll owing in vivo administration of IMO -2125 
included increased plasma concentrations of IL -12 and IP -10; changes in trafficking of white 
blood cells (WBCs), particularly a transient decrease peripheral blood lymphocytes at [ADDRESS_960829]-dose; and increased ex pression of the activation marker CD69 on T cells, B cells, and NK 
cells (Trombino  2007b).  
Peripheral blood mononuclear cells, including pDCs and B cells, were isolated from healthy 
volunteers and stimulated in vitro with IMO -2125  for 6 to 48 hours (Bhaga t 2007a, 
Bhagat  2007b, Bhagat 2007c, Bhagat 2007d, Bhagat 2007e). IFN -Î± and IP -[ADDRESS_960830] ivation, normal T cell 
expressed and secreted (RANTES). Further indications  of in vitro immune stimulation in these 
cultures were the induction of B cell proliferation and increased expression of CD86 and CD69 
activation markers on B cells and pDCs (Bhagat  2007f, Bhagat 2007g; Bhagat 2007h).  
IMO -2125  Page 41 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS]. Studies in Model s of Disease  
The nonclinical  rational e for use of IMO -2125 in immune oncology comes from mechanism of 
action studies in vitro and in  vivo and from anti tumor activ ity in mouse xenograft models. 
Clinical p roof of concept is derived from studies in patients with chronic hepatitis C virus (HCV) 
infection .  
â€¢ Cytokine induction profile in in vitro studies using human PBMCs and pDCs show 
IMO -[ADDRESS_960831] been implicated 
in the intratumoral mechanism of action ; 
â€¢ Induction of IFN -Î± and IP -10 in cynomolgus monkeys, with activation of T cells, 
B cells, and NK cells ; 
â€¢ Tumor growth inhibition in murine xenograft models and induction of splenic 
CD8+  lymphocytes in combination with an anti -CTLA -4 mAb ; 
â€¢ Induction of IFN -Î± and IP -[ADDRESS_960832] been conducted with systemic administration of IMO -2125; both 
studies were conducted in patients wit h HCV infection . IMO -2125 was administered s.c. at 
dosages  up to 0.48 mg/kg/week  in 96 patients . Full details are provided in the Investigatorâ€™s 
Brochure . The most common adverse events (AEs) were mild to moderate flu -like symptoms and 
injection site react ions (ISRs). 
4.6. Rationale for Study Design and Selection of Dose  
This study will be a 2 -part study  with two treatment arms.  The primary objective of Phase 1 is to 
characterize the safety and determine a recommended Phase 2 dose (RP2D) of IMO -2125 when 
administered in combination with ipi[INVESTIGATOR_707176].  The maximum tolerated dose 
(MTD )/RP2D for IMO -2125 may differ between the combination of IMO -2125 and ipi[INVESTIGATOR_707177] -2125 and pembrolizumab. The primary objective of Phase 2 is  to 
assess preliminary clinical activity of each combination at the respective RP2D(s) in patients 
with metastatic melanoma that is not responsive to PD -1 inhibitor thera pi[INVESTIGATOR_014], using  Response 
Evaluation Criteria in Solid Tumors  v1.1 (R ECIST ; Eisenhauer, 2009) . 
IMO -2125  Page 42 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    4.6.1. Rationale for t his Phase 1/[ADDRESS_960833] of TLR9 , 
stimulates both the innate and adaptive immune systems, and induces the expression of an array 
of endogenous cytokines and chemokines, including IL-1Î², IL -6, IL -12, IFN-Î±, IFN -Î³, IP-10, 
TNF -Î±, and MCP -1. In preclinical studies IMO -2125 has shown dose -dependent anti tumor 
activity associated with changes in the tumor microenvironment, increased T -cell infiltration, 
and induction of durable, tumor -specific memory. In combination with anti -CTLA -4 or 
anti-PD-1, IMO -2125 has shown greater anti tumor activity tha n with either agent alone. 
Therefore , the combination of IMO -2125 with either ipi[INVESTIGATOR_707178] a 
novel therapy to benefit patients with metastatic melanoma.   
[IP_ADDRESS]. Rationale for I ntratumoral I njection  of IMO -[ADDRESS_960834] shown limited activity as cancer therapeutics 
alone or in combinations with other agents (Smit h, 2014; Chan, 2015). Poor clinical responses 
after intravenous ( i.v.) administration may be due, in part, to the fact that activated T  cells f ailed 
to migrate to the tumor (Lou, 2011). Ea rly studies by [CONTACT_707247] (2009) , showed that agonists of 
TLR9 were most effective when administered in close proximity to tumor antigens, and that i.v. 
and s.c. routes of TLR9 agonist administration were less eff ective than peri -tumoral injections 
(den Brok, 2004; Baines and Celis 2003; Heckel smiller, 2002).  
In preclinical models, intratumoral IMO -2125 administration leads to a dose -dependent decrease 
in treated and distant tumor volume, increase in infiltrating C D8+ T cells, and specific cytotoxic 
T cell responses against tumor antigens which are associated with durable tumor specific 
immune memory. Intratumoral IMO -2125 administration modulates the tumor 
microenvironment by [CONTACT_707248] -infiltrating lymphocytes ( TILs ) and by 
[CONTACT_707249]. The combination of intratumoral IMO -2125 and an 
anti-CTLA -4 mAb resulted in improved inhibition of tumor growth, regression of systemic lung 
metastases and infiltration of TILs versus monotherapy with either agent. The combination of 
intratumoral IMO -2125 with an anti -PD-1 antibody also showed more potent antitumor activity 
than either agent alone (Wang CRI -CIMT -EATI -AACR M eeting, 2015; Wang, 
AACR -NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 
2015) .  
4.6.2. Rationale for Population  
Despi[INVESTIGATOR_707179], only a small minority of patients 
experience dramatic clinical benefit from any of the available immunotherapi[INVESTIGATOR_707180] . 
The combination of ipi[INVESTIGATOR_707181], but at 
the expense of significant additive toxicity, and median survival is still less than a year (Larkin , 
2015). Thus, new treatment approaches that build on the now -established proof of concept for 
immunotherapy are sorely needed . Patients who relapse after treatment with a PD -[ADDRESS_960835] a particular unmet need since no therapy has been shown to be effective in this setting .  
IMO -2125  Page 43 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    4.6.3. Rationale for Design  
The Phase 1/2 design allows for optimal dose  selection  for IMO -2125 in combination with  
ipi[INVESTIGATOR_707182], followed by [CONTACT_707250]2D (s) to 
evaluate preliminary efficacy and to generate addition al long -term safety follow  up data.  
4.6.4. IMO -[ADDRESS_960836]  been administered s.c.  to 96 patients with chronic HCV infection . 
These patients received dosages  ranging from 0.04 to 0.48 mg/kg. Based on this prior human 
safety experience, a dosage  of 0.08 mg/kg was selected as the start ing dose and then set as a 
fixed dose by [CONTACT_7702] a conservative  patient weight of 60 kg for a calculated starting dose level 
of 4.8 mg. A lower dose level was selected as the fixed starting dose level (4  mg) as an added 
safety margin.  
IMO -[ADDRESS_960837] 3 weeks of 
Cycle 1 , followed by [CONTACT_707234] 5, 8, 11, 17, 23, and 29 (Day 1 of 
Cycles  2 through 7). Ipi[INVESTIGATOR_195679] a  90-minute  i.v. infusion at 3  mg/kg 
once every [ADDRESS_960838] label , after which continued administration is at the discretion of the 
Investigator  for patients in the IMO -2125 + pembrolizumab treatment arm. P atients who initiated 
treatment at the 2  mg/kg dose may continue treatment using either the 200  mg dose or the 
2 mg/kg dose . If institution al practice requires certain patients to be treated using weight -based 
pembrolizumab dosing, those patients may be treated with the 2 mg/kg dose.  
Pembrolizumab safety compares favorably to ipi[INVESTIGATOR_125] (Robert, 2015), thus dosing of 
IMO -[ADDRESS_960839] (Parry, 2005) .  
 
IMO -2125  Page 44 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    5. STUDY OBJECTIVES  
5.1. Primary Objective  
The primary objective of Phase 1 is to characterize  the safety and determine an RP2D  of 
IMO -2125 when administered in combination with ipi[INVESTIGATOR_707183]. The MTD and RP2D 
for IMO -2125 may differ between the combination of IMO -2125 and ipi[INVESTIGATOR_707184] -2125 and pembrolizumab. 
The primary objective of Phase 2 is to assess the preliminary clinical activity  of IMO -2125 in 
combination with ipi[INVESTIGATOR_707185]2D(s) 
in patients with metastatic melanoma  that is not responsive to PD -[ADDRESS_960840] v1.1 ( Eisenhauer, 2009) . 
5.2. Secondary O bjectives  
The secondary objectives of Phase 1 are to determine the plasma pharmacokinetics (PK) of 
single -dose IMO -2125 and repeat -dose IMO -2125 administered by  [CONTACT_707251][INVESTIGATOR_707133] . An additional secondary objective of Phase 1 
is to describe an y preliminary antitumor activity . 
The secondary objectives of Phase 2 are to further assess  the safety and tolerability o f IMO -2125 
in combination with ipi[INVESTIGATOR_707186] -related Response 
Evaluation Criteria in Solid Tumors ( irRECIST ) and RECIST v1.1, overall survi val (OS), OS at 
6 and 12 months , PFS , PFS at 6  and 12 months, durable response rate (DRR), duration of 
response (DoR) , and disease control rate (DCR) . 
5.3. Exploratory Objectives  
The exploratory objectives of Phase 1 and 2 are to assess patient reported outcomes (PRO ), 
pre- and post -treatment blood biomarkers , pre- and post -treatment tumor biopsies for 
immunological assessment,  and explore any potential association between th ese biomarker 
measures and anti tumor activity.  In addition, anti-IMO -2125, anti -ipi[INVESTIGATOR_125], and 
anti-pembrolizumab antibody formation will be assessed . 
IMO -2125  Page 45 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960841]  v1.1.  
6.2. Secondary Endpoints  
The secondary endpoint s in Phase 1 are:   
â€¢ PK a ssessments for IMO -2125;  
â€¢ ORR assessed using irRC and RECIST v1.1  
The secondary endpoints in Phase 2 include : 
â€¢ Safety and tolerabi lity (type and frequency of AEs, clinical laboratory values, 
electrocardiograms [ ECGs ], and vital sign measurements)  for each combination;  
â€¢ Duration of response using RECIST  v1.1;  
â€¢ ORR and duration of response using irRECIST ;  
â€¢ PFS, defined as time from the initiation of treatment to disease progression by 
[CONTACT_299602] v1.1, or death from any cause;   
â€¢ PFS at 6 and 12 months ; 
â€¢ OS, defined as time from initiation of treatment to death  from any cause;   
â€¢ OS at 6 and 12 months ;  
â€¢ Durable response r ate by [CONTACT_299602] v1.1, defined as the rate of complete 
response ( CR) plus  partial response ( PR) lasting at least [ADDRESS_960842] 12 months of study ; 
â€¢ Disease control rate by [CONTACT_299602] v1.1, defined as the rate of CR, PR, or 
stable disease (SD).   
6.3. Exploratory Endpoints  
The pre - and post -treatment exploratory endpoints of Phase 1 and 2 include, but are not limited 
to, PRO using the European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire -CORE 30 (EORTC QLQ -C30), blood biomarkers ( e.g., IFN-Î³ and other plasma 
cytokines ) and tumor markers  to assess any potential association between immune response to 
IMO -2125 at the Week 8 tumor biopsy with tumor response in both injected and uninjected 
tumor lesions at Week 13 or at Week  23 (depending on the protocol version under which the 
patients were enrolled).  
IMO -2125  Page 46 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    7. PATIENTS TO BE RECRU ITED  
7.1. Patient Recruitment  
Enrollment during the Phase 1 dose -escalation p ortion and the Phase 2 portion of the study is 
open to adult patients with advanced/me tastatic melanoma.  
Patient selection and recruitment will be organized and overseen by [CONTACT_707252] l of the study protocol by [CONTACT_291288] B oard (IRB)  or Ethics 
Committee (EC) . All patients who sign an informe d consent , are screened , and either qualify  or 
do not qualify  for the study will be documented in the screening and enrollment log . Appropriate 
documentation will be made indicating the willingness of the patient to participate and cons ent to 
the conduct of the study  before initiating any study -related procedures.  
7.2. Inclusion Criteria 
To be eligible for this study, all patients must meet all of the following inclusion criteria. These 
criteria  apply to both the Phase [ADDRESS_960843] histologically confirmed metastatic melanoma with measurable, 
stage  III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease . 
2. Patients must have  symptomatic or radiographic  progression during or after treatment 
with a PD -(L)[ADDRESS_960844] PD -(L)[ADDRESS_960845] 21 days. 
b. Prior BRAF or MEK inhibitor treatment is not required. However, for patients with 
known BRAF status:  
i. Those with BRAF wild  type may have had a maximum of  two previous systemic 
regimens for the treatment of melanoma .  
ii. Those wit h a BRAF mutation may have had a maximum of  three previous 
systemic regimens for the treatment of melanoma.  
c. Prior ipi[INVESTIGATOR_707142] . 
d. Previous treatment with either a PD -1 inhibitor  (for patie nts enrolling on the 
IMO -2125 +  pembrolizumab combination) or CTLA -4 inhibitor  (for patients 
enrolling on the IMO -2125 + ipi[INVESTIGATOR_43809]) should not have been 
accompanied by [CONTACT_2715] -limiting toxicity  (DLT)  for which permanent discontinuation is 
recommended (per USPI) .  
i. Patients with a history of Grade â‰¥2 gastrointestinal symptoms (e .g., diarrhea, 
colitis) during prior  checkpoint inhibitor treatment should be discussed with the 
Idera Medical Monitor during the Screening Period before starting study 
treatment.  
3. Phase [ADDRESS_960846]  two measurable tumor lesions â‰¥ 1.[ADDRESS_960847] one measurable lesion (per 
RECIST v1.1) which may be the same site that is used for the intratumoral injections . 
4. Patients must be â‰¥ 18 years  of age . 
IMO -2125  Page 47 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960848] Eastern Cooperative Oncology Group ( ECOG) Performance Status  â‰¤2 
(Oken, 1982)  (Section  21.1) . 
6. Patients must meet the following laboratory criteria: 
a. Absolute neutrophil count (ANC) â‰¥ 1.5 x 109/L (1500/mm3) 
b. Platelet count â‰¥ 75 x 109/L (75,000/mm3) 
c. Hemoglobin â‰¥ 8.0 g/dL  (4.96 mmol/L)  
d. Serum creatinine â‰¤ 1.5 x uppe r limit of normal (ULN) or calculated  creatinine 
clearance â‰¥ 60 mL /minute  
e. Aspartate aminotransferase (A ST) â‰¤2.[ADDRESS_960849]; alanine aminotransferase ( ALT ) 
â‰¤2.[ADDRESS_960850];  AST/ALT < [ADDRESS_960851] if liver involvement  
f. Serum  bilirubin â‰¤ 1.[ADDRESS_960852], except i n patients with Gilbertâ€™s Syndrome who must 
have a total bilirubin < 3 mg/dL  
7. Women of childbearing potential (WOCBP) and men must agree to use effective 
contraceptive methods from Screening throughout the study treatment period and until at 
least [ADDRESS_960853] dose of pembrolizumab. 
Non-childbearing potential is defined as a woman  who meets either  of the following 
criteria: a) postmenopausal state defined as no menses for 12 months without an 
alternative medical cause, or b) documented hysterectomy, bilateral tubal ligation, or 
bilate ral oophorectomy.  
Effective contraception methods are defined as one  of the following:  
a. True abstinence, defined as refraining from heterosexual intercourse, when this is 
in line with the preferred and usual lifestyle of the patient . Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of a trial, and withdrawal are not acceptable methods 
of contraception.  
b. Condoms and spermicide  
c. Diaphragm and spermicide  
d. Oral or implanted hormonal  contraceptive (e. g., Implanonâ„¢)  
e. An intra -uterine device (IUD)  
8. WOCBP must have a negative pregnancy test (serum or  urine) prior to the first dose of 
study treatment. 
9. Patients must be willing and able to sign the informed consent and comply with the study 
protocol . 
10. Patients must have a n anticipated life expectancy >3 months . 
IMO -2125  Page 48 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    7.3. Exclusion Criteria  
Patients meeting any of the following criteria will be excluded from the study:  
1. Patients who have received prior therapy with a TLR agonist , excluding topi[INVESTIGATOR_12450]. 
Patients who have received experimental vaccines or other investigational immune 
therapi[INVESTIGATOR_707143].  
2. Patients who have received systemic treatment with IFN -Î± within the previous 6 months 
prior to enrolling into this study . 
3. Patients with known hypersensitivity to any oligodeoxynucleotide . 
4. Patients with active autoimmune disease requiring disease -modifying therapy . 
5. Patient s requiring concurrent systemic steroid therapy higher t han physiologic dose  
(7.5 mg/day of prednisone) . 
6. Patients with any form of active primary or secondary immunodeficiency . 
7. Patients with another primary malignancy that has not been in remission for at least 
3 years. The following are exempt from the 3 year limit: non -melanoma skin cancer, 
curatively treated localized prostate cancer with non -detectable prostate -specific antigen , 
cervical carcinoma in situ on biopsy or a squamous intraepi[INVESTIGATOR_707144] 
(Pap) smear, and thyroid cancer (except anaplastic) . 
8. Patients with active systemic infections requiring antibiotics or active hepatitis A, B, or 
C. 
9. Patient s who are h epatitis B surface antigen  positive . 
10. Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.  
11. WOCBP who are  pregnant or breast feeding . 
12. Patients who have had prior anaphylactic or other severe infusion reaction associated 
with human antibody administration . 
13. Patients with known central nervous system, meningeal, or epi[INVESTIGATOR_408180] . Patients with 
stable brain metastases following definitive local treatment are eligible if steroid 
requirement is less than 7.5 mg/day of prednisone (or equivalent).  
14. Patients with impaired cardiac function or clinically significant cardiac disease such as:  
a. [LOCATION_001] Heart Association  Class III or IV cardiac disease, including preexisting 
clinically significant ventricular arrhythmia, congestive heart failure , or 
cardiomyopathy  
b. Unstable angina pectoris â‰¤ 6 months prior to study participation 
c. Acute myocardial infarction â‰¤ 6 months prior t o study participation 
d. Other clinically significant hear t disease (i.e., Grade â‰¥ 3 hypertension, history of labile 
hypertension, or poor compliance with an anti -hypertensive regimen ) 
15. Ocular melanoma.  
IMO -2125  Page 49 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    8. STUDY DESIGN 
8.1. Overview  
This is a  two arm, open- label  Phase 1/[ADDRESS_960854] 
experienced symptomatic or confirmed radiographic progression during or after treatment with 
an anti -PD-(L)1 agent ( alone or in combination) will be eligible. Prior BRAF or MEK inhibi tor 
treatment is not required. The study will be conducted in two  parts : a dose -escalation portion 
(Phase 1) to evaluate safety and tolerability of multiple dose levels and a Phase 2 portion to 
assess preliminary efficacy .  
8.1.1. Phase 1  
The Phase 1 portion of the stu dy will explore escalating dose levels  of IMO -2125 ( from 4 to 
32 mg  with de -escalation to 2 mg allowed  for each IMO -2125 combination). For each cohort, 
IMO -2125 will be administered as a once- weekly  intratumoral injection for 3 cons ecutive weeks  
in Cycle  1, followed by [CONTACT_707253] 5, 8, 11, 17, 23, and 29 ( Day 1 of 
Cycles 2 through 7) . Both ipi[INVESTIGATOR_707187] 3  weeks beginning Day 1 of Cycle 1 Week 2. Continued pembrolizumab dosing following 
the study period is permitted at the discretion of the In vestigator  for patients in the IMO -2125 + 
pembrolizumab treatment arm. The dosing schedule is summarized in Table 4. 
Table  4: Schedule of Dosing for Phase 1 and Phase 2  
 Cycle  
 1 2 3 4 5 6 7 
Study week  1 2 3 4 5 6 7 8 9 10 11 12 13 17 23 29 
IMO -2125 + ipi[INVESTIGATOR_707136] -2125  X X X - X - - X - - X - - X X X 
Ipi[INVESTIGATOR_125]  - X - - X - - X - - X - - - - - 
IMO -2125 + pembrolizumab  
IMO -2125  X X X - X - - X - - X - - X X X 
Pembrolizumab  - X - - X - - X - - X  X1 
Note: On weeks when the combinations are administered, administration of ipi[INVESTIGATOR_707137], followed by [CONTACT_58444] -2125. IMO -[ADDRESS_960855] occur within a Â± 2 day window of the scheduled dosing 
day.  
1 For patients in the IMO -2125 + pembrolizumab treatment arm, continued pembrolizumab dosing per the approved 
product label is permitted at the discretion of the Investigator.  
 
Patients assigned to [ADDRESS_960856] 
not yet reached the end of the Treatment Period may receive the Week 17, 23, and 29 injections 
at the discretion of the treating Investigator .  
IMO -2125  Page 50 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Each cohort will  be monitored for the occurrence of DLTs . The DLT  evaluation period will be 
Cycle 1  (Weeks 1 through 4) . If a patient discontinues study participation before the DLT 
evaluation period is finished due to reasons other than experiencing a DLT, that patient m ust be 
replaced so that the cohort may be properly evaluated . More information about the review of 
DLTs and the escalation of dose levels between cohorts is provided in Section  8.1.3, 
Section  8.1.4, and  Section  8.1.5. 
There are 3 patients planned per cohort. During Phase 1 , the Sponsor will assign patients to a 
treatment arm ( IMO -2125 + ipi[INVESTIGATOR_707188] -2125 + pembrolizumab) by [CONTACT_9084]. 
The Sponsor will m aintain a prioritization schedule for cohort assignment in a separate 
document. A Cohort Review Committee (CRC) will be convened prior to each dose level 
escalation to review the available data and provide recommendations on st udy conduct. After 
completing  the DLT evaluations for all planned IMO -[ADDRESS_960857]  v1.1, of IMO -2125 + ipi[INVESTIGATOR_125] , IMO -2125 +  pembrolizumab, and any additional 
combinations that are studied in Phase 1. T he dose level of IMO -[ADDRESS_960858] 60 patients treated at the IMO -2125 + ipi[INVESTIGATOR_707140]2D . This will 
include at least 21 patients in the primary IMO -2125 + ipi[INVESTIGATOR_707141] -evaluable populati on 
(as defined in Section  16.2) and up to 20 patients in the secondary IMO -2125 + ipi[INVESTIGATOR_707189] -evaluable population. 
In the IMO -2125 + pembro lizumab Phase 2 cohort, enrollment will continue until 21  patients in 
the IMO -2125 + pembrolizumab efficacy -evaluable population have been treated at the 
IMO -2125 + pembrolizumab RP2D .  
Phase [ADDRESS_960859] one efficacy evaluation for reasons 
other than toxicity, then that patient will be replaced with the replacement  assigned to the same 
treatment arm and dose level as the patient who dropped out  early.  
IMO -2125  Page 51 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Combination therapy in Phase 2 will continue using the same schedule as Phase  1 (Table 4 ). 
8.1.3. Dose E scalation and Stoppi[INVESTIGATOR_707190] f ive dose levels for IMO -2125 are initially planned ( Table 5).  
Table  5: Treatment Doses to be Investigated  
Dose Level  IMO -2125  Ipi[INVESTIGATOR_707149]  
-1 2 mg  3 mg/kg  200 mg  
+1 4 mg  3 mg/kg  200 mg  
+2 8 mg  3 mg/kg  200 mg  
+3 16 mg  3 mg/kg  200 mg  
+4 32 mg  3 mg/kg  200 mg  
 
In Phase 1, t he study will enroll patients in planned cohorts of 3, beginning at Dose Level +1 for 
the ipi[INVESTIGATOR_707191] +2 for the pembrolizumab  treatment 
arm once safety of the IMO -2125 + ipi[INVESTIGATOR_707192] . 
A charter will be used to guide the CRCâ€™s decision- making.  
Additionally, if, due to observed toxicity, it proves difficult to provide IMO -[ADDRESS_960860] treatment cycle of 
each cohort ( Section  8.1.5). Using a prior beta(1,1) distribution of the DLT rate Î´  i for each dose 
level i, the MTD is defined as the highest dose level  for which the mean of the posterior 
distribution of toxicity is closest to but less than 25% among all the evaluated doses i for which 
Pr (Î´ i > 0.25 | data)  <0.80. 
The RP2D (s) will be selected from  dose level (s) at or below the MTD. Additional dose levels  
may be studie d if the MTD(s) have not been reached and pharmacodynamic activity is deemed to 
be inadequate.  At the time of completion of the Phase 1 portion of the study , an analysis of the 
data will be performed .  
[IP_ADDRESS]. Phase 2 Stoppi[INVESTIGATOR_707193]2D level(s) established in the Phase 1 portion of the 
study  for a total of approximately 90 to 100 patients  enrolled in the study . DLTs will be 
continuous ly monitored throughout the study . Assuming a prior beta  (0.6, 1.4) distribution for 
the overall toxicity rate for a treatment, a Phase 2 arm will terminate if the Pr (Î´ t > 0.25 | data) 
>0.80, where Î´ t is the DLT rate attributable to the treatment. The decision rule for terminating 
due to toxicity is presented in Table 6. The method used to produce the decision rule and 
operating characteristics was designed by [CONTACT_203320] ( 2006) . 
Table  6: Phase [ADDRESS_960861]-cycle DLTs or more  3 4 5 6 7 8 9 10 
Stop if this many patients (or fewer) have begun treatment   7 10 13 17 20 24 27 29 
IMO -2125  Page 52 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960862] cycle of study treatment, a CRC meeting will be convened to 
review all safety data and decide whether DLTs were observed . Based on the CRCâ€™s 
adjudication of DLTs observed in a cohort, they  will guide deci sions on the dose level that the 
subsequent cohort will be administered.  
A review of all relevant available data will occur  between the Sponsor and participating 
Institution(s) at least monthly for the duration of the study .  
8.1.5. Definition of Dose -limiting T oxicities  
Toxicity will be evaluated according to the National Cancer Institute ( NCI) Common 
Terminology Criteria for AEs  (CTCAE ) v4.03 toxicity criteria.  Dose -limiting toxicities are 
defined as those events that will require dose modification; therefore, D LT criteria should be 
referenced throughout the Phase 1 and 2 portions  of the study. The DLT  evaluation period will 
be Cycle  1 (Weeks 1 through 4) . 
For the purpose s of dose level escalation and determination of the MTD (s), only DLTs (as 
defined below) that  occur during the first  cycle  of treatment will be considered in decision s 
regarding dose level escalation ; however, DLTs or other clinically significant toxicities that 
occur throughout the observation period will be considered when determining the RP2D(s ) for 
use in this trial and in subsequent clinical trials . 
During Cycle 1  of the dose escalation portion, if two  of the three patients in a cohort experience 
the same Grade 2, treatment -related AE, then subsequent increases in dose level will proceed in 
increments less than 100%. If more than one  cohort is trea ted at the same dose level and greater 
than 67% of patients treated at that dose level experience the same Grade 2 treatment -related AE  
(Table 7) , dose level escalation will proceed in increments less than 100%. In such a case, 
specific dose level increments will be decided by [CONTACT_10186].  
Protocol -defined hematologic DLTs include:  
â€¢ CTCAE Grade 4 neutropenia â‰¥ 7 days ; 
â€¢ CTCAE Grade 3 or 4 neutropenia with fever â‰¥ 38.5Â°C ;  
â€¢ CTCAE Grade 3 thrombocytopenia with bleeding;  
â€¢ CTCAE Grade 4 thrombocytopenia  â‰¥7 days . 
Protocol -defined non- hematologic DLTs include: 
â€¢ Grade â‰¥ 3 vomiting or nausea â‰¥ 14 days despi[INVESTIGATOR_58348] -emetic 
treatments ; 
â€¢ Grade â‰¥ 3 diarrhea â‰¥ 14 days despi[INVESTIGATOR_58348] -diarrheal treatments  which 
should include infliximab as per institutional guidelines ; 
â€¢ Serum creatinine > 3.[ADDRESS_960863] ; 
IMO -2125  Page 53 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    â€¢ AST or ALT > [ADDRESS_960864];  in patients with liver metastasis who entered the study with 
Grade [ADDRESS_960865] or ALT increase â‰¥50% relative to baseline 
and lasting â‰¥1 week;  
â€¢ Bilirubin â‰¥ 3.[ADDRESS_960866] ; 
â€¢ Bilirubin â‰¥ 2.[ADDRESS_960867] with AL T >[ADDRESS_960868] in patients without liver meta stases ; 
â€¢ Other  non- hematologic toxicities of  Grade â‰¥ 3, except for the following:  
âˆ’ AEs related to underlying disease ; 
âˆ’ CTCAE Grade 3 fatigue  <14 days ; 
âˆ’ Alopecia;  
âˆ’ Isolated, asymptomatic elevations in biochemistry laboratory values lasting 
â‰¤14 days.  This includes  electrolyte abnormalities that respond to medical 
intervention. 
Ipi[INVESTIGATOR_125] -related DLTs:  
â€¢ Grade â‰¥ 4 immune -mediated dermatitis (except skin reaction at site of injection) ; 
â€¢ Grade â‰¥ 3 immune -mediated endocrinopathy (with the exception of  Grade 3 
autoimmune thyroiditis that resolves to Grade 1 or ba seline within 28 days of onset) ; 
â€¢ Grade â‰¥ 3 immune -mediated enterocolitis ; 
â€¢ Grade â‰¥ 3 immune -mediated hepatitis with the exception of Grade 3 
immune -mediated hepatitis that resolves to Grade 1 or baseline  within 28 days of 
onset ; 
â€¢ Grade â‰¥ 3 immune -mediated neuropathy, pancreatitis, meningitis, nephritis , and 
pneumonitis that are considered to be possibly, probably, or definitely related to study 
therapy as  determined by [CONTACT_737] ; 
â€¢ Any persistent IMO -2125- related toxicity that lead s to a delay of scheduled (per 
standard of care) ipi[INVESTIGATOR_125] > 14 days . 
Pembrolizumab -related DLTs:  
â€¢ Grade â‰¥ 3 pneumonitis or recurrent Grade 2 pneumonitis ;  
â€¢ Grade â‰¥ 3 nephritis ;  
â€¢ Grade â‰¥ 3 infusion- related reactions ;  
â€¢ Inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent 
per day within 12 weeks ; 
â€¢ Any Grade â‰¥ [ADDRESS_960869] be  assessed for attribution based on the known toxicity profiles for ipi[INVESTIGATOR_125], 
pembrolizumab, and IMO -2125. If assessment can be clearly attributed to one of the drugs in the 
combination, then dosing should be interrupted and the toxicity should be followed until 
IMO -2125  Page 54 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    resolution, stabilization, or return to baseline. Treatment with the other agent  may con tinue 
during this time period. If attribution cannot be clearly ascribed to one agent versus the other, 
then both IMO -2125 and ipi[INVESTIGATOR_125] (or pembrolizumab) should be stopped and the toxicity 
should be followed until resolution, stabilization, or return to baseline. If treatment is to be 
resumed, then re -initiation criteria must be met. If the DLT was  clearly related to IMO -[ADDRESS_960870] be administered at a lower dose 
level (a minimum reduction of at least 1 dose level). If the DLT recurs after a dose level 
reduction, then treatment should be discontinued.  
Patients who experience a non -laboratory, IMO -2125- related DLT must be evaluated weekly, at 
a minimum, until resolution to Grade â‰¤ [ADDRESS_960871]. For abnormal laboratory values that 
qualify as DLT s, patients will be followed twice weekly until values return to Grade â‰¤ [ADDRESS_960872].  
Criteria for r e-initiation of study treatment following occurrence of a DLT  are as follow s: 
â€¢ ANC must be â‰¥ 1.5 x 109/L (1500/Î¼L) ; 
â€¢ Platelets must be â‰¥ 75 x 109/L (75,000/Î¼L) ; 
â€¢ All clinically significant non -hematologic toxicities for which a causal association to 
study treatme nt cannot be ruled out must be  Grade â‰¤ 1 (except alopecia) or returned to 
baseline.  
If the patient does not meet these criteria, dosing will be delayed and the patient should be 
re-evaluated with in 48 to 72 hours. If the next cycle is delayed by [CONTACT_726] 21 days  for toxicity , 
the patient should be  removed from study treatment. In these situations, if the patient is 
experiencing clinical benefit and has a favorable risk/benefit profile, study treatment with 
IMO -2125 may be continued if agreed upon by [CONTACT_66229]. 
8.1.6. Safety Assessment for Immunologically Related Toxicity 
Based on an incidence of G rade 3 or greater immune- mediated AEs associated with use of  
ipi[INVESTIGATOR_707194] 12% to 15%, the following safety precautions 
will be followed . Examples of relevant toxicities include the followin g: enterocolitis, hepatitis, 
dermatitis, neuropathy, endocrinopathy, nephritis, pneumonitis, pancreatitis, non- infectious 
myocarditis, uveitis , and  iritis.  
During dose level escalation, if any of the following is observed, the CRC will be convened to 
review all safety findings for all patients treated in that cohort and all previous cohorts, including 
those events that occurred beyond C ycle 1, to guide next steps. 
â€¢ If more th an one patient experiences a Grade â‰¥ 3, immune -related adverse event 
(irAE) in a coho rt of 3 patients;  
â€¢ If more than  two patients experience a Grade â‰¥ 3 irAE in cohorts of 6 patients.   
During the P hase 2 portion of the trial, if the incidence of Grade â‰¥ 3 irAEs  observed in C ycle 1 or 
in subsequent cycles of treatment exceeds 2 5%, the CRC will be convened to review all safety 
findings from all patients treated in the study to guide next steps.  
IMO -2125  Page 55 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    8.2. Duration of Study  
8.2.1. Treatment Duration  
The study treatment period is 29 weeks  (as per Table  4) in the absence of  intolerable toxicity or 
unequivocal disease  progression. Continued treatment with pembrolizumab following the 
completion  of IMO -2125  study treatment is at the discretion of the Investigator  for patients in the 
IMO -2125 + pembrolizumab treatment arm.  
8.2.2. Study Duration  
The study ends approximately  [ADDRESS_960873] v1.1 
progressive disease (PD), start of a subsequent anti -cancer treatment regimen, wi thdrawal of 
consent , death, or Sponsor notification that follow -up is no longer required, whichever comes 
first. Best response to first subsequent therapy , AEs which are Grade â‰¥ 3, and concomitant 
medications used to treat these AEs, will also be captured during the follow -up phase of the 
study ( Table  1 and Table  2).  
After documentation of PD or use of a subsequent anti -cancer treatment regimen,  all patients will 
be contact[CONTACT_80077] 3 months for survival follow -up until the site is  notified by [CONTACT_707237] -up is no longer  required.  
8.3. Number of Patients   
The study will enroll approximately 90 to 100 patients. It is estimated that approximately 
30 patients will be treated in the dose -finding portion of Phase 1 and approximately 60 to 
70 additional  patients will be treated in the Phase 2 portion of the study.  
8.4. Benefits and Risk Assessment  
Patients with advanced melanoma who relapse after immunotherapy (and a BRAF or MEK 
inhibitor , if indicated) have an estimated survival that is measured only in months with no 
approved therapeut ic options . Preliminary experience with the IMO -2125 + ipi[INVESTIGATOR_707195] (Uemera, 2017) . Based on these data, 
the benefit:risk is likely to be favorable if the efficacy objectives of the study are  achieved .    
 
IMO -2125  Page 56 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    9. STUDY PROCEDURES BY [CONTACT_707254] a listing of the procedures to be performed at each study visit. See the Schedule s of 
Evaluations ( Table 1 for Phase 1 and Table 2 for Phase 2 ) to view the study  procedures in detail 
in a tabular  format.  
9.1. Screening ( Up to 21 Days Before Day 1 of  Week 1, Cycle 1 ) 
The following information will be captured at the Screen ing V isit: 
â€¢ Informed consent  
â€¢ Inclusion/exclusion criteria  
â€¢ Demography and m edical history , including melanoma history  and melanoma 
treatment history  
â€¢ Physical exam ination  (should include, but not be limited to, areas related to the 
inclusion/exclusion criteria  in addition to height and body weight ) and assessment of 
melanoma lesions  
â€¢ ECOG p erformance status  (Oken, 1982) ( Section  21.1)  
â€¢ Target tumor lesions will be identified and assessed per RECIST v1.1 criteria.  
â€¢ The injected and non -injected tumor lesions for biopsy  (biopsies optional in Phase 2)  
will be identified and r ecorded on the electronic case report form ( eCRF ), if 
performed . 
â€¢ Tumor biopsies  are to  be performed by [CONTACT_707255] ( e.g., core or punch)  or Fine 
Needle Aspi[INVESTIGATOR_1516] (FNA)  within [ADDRESS_960874] treatment  
â€¢ Radiologic al assessment  
â€¢ Vital signs  
â€¢ Electrocardiogram   
â€¢ Complete blood count (CBC) with differential and chemistry profile (including liver 
function tests [LFTs])   
â€¢ Complement (total complement activity 50  [CH50 ], complement component 3 [ C3], 
and complement component 4 [ C4]) 
â€¢ Coagulation tests  
â€¢ Thyroid function profile  
â€¢ Serum or  urine pregnancy test for WOCBP  
â€¢ Urinalysis with microscopic exam 
â€¢ AEs 
IMO -2125  Page 57 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    9.2. Cycle 1 Dosing D ays (Weeks 1, 2, and 3)  
Adverse event  and concomitant medication monitoring will be performed on an ongoing basis. 
9.2.1. Pre-dose  
Before dosing,  the following will be performed:  
â€¢ Physical examination (any areas related to the inclusion/exclusion criteria  and body 
weight ) and assessment of melanoma lesions  (Week 1 only)  
â€¢ Vital signs  
â€¢ ECOG Performance Status (Week 1 only)  
â€¢ CBC  with differential and chem istry profile (including LFTs )  
â€¢ Coagulation tests (Week 1 only)  
â€¢ Thyroid function profile (Week 2 only)  
â€¢ ECG (Week 2 only)  
â€¢ AEs 
â€¢ Concomitant medication monitoring  
â€¢ PK assessments (see Table 3)  
â€¢ Immunogenicity  assessments  (Week 1 only)  
â€¢ In Phase 2, all tumor biopsies are optional. See Section 13.2 and the Laboratory 
Manual for details on the collection of biopsies and analyses of biomarkers.  
â€¢ Blood biomarker samples  
âˆ’ Week 1: Blood for PBMC and serum for cytokines  
âˆ’ Week 2: Serum for cytokines  
â€¢ PRO using the EORTC QLQ -C30 (Week 1 only)  
9.2.2. Study Drug Administration 
â€¢ IMO -2125 by [CONTACT_707256]  (Day 1 of Week 1, Week 2, and Week 3)  
â€¢ Ipi[INVESTIGATOR_707133] i.v. infusion ( Day 1 of Week 2 only)  
9.2.3. Post intratumoral  IMO -2125 Injection  
â€¢ AEs (including DLTs)  
â€¢ Week 1 only: blood biomarker samples collected 4 hours (serum for cytokines) and 
[ADDRESS_960875] -dose (blood for PBMC and serum for cytokines) .  
â€¢ In Phase 2, all tumor biopsies are optional. See Section 13.2 and the Laboratory 
Manual for details on the collection of biopsies and analyses of biomarkers.  
IMO -2125  Page 58 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    â€¢ PK assessments ( Weeks 1 and 2 only; see Table 3 ) 
â€¢ ECG (Week 2 only; [ADDRESS_960876] -dose IMO -2125 administration ) 
9.3. Cycle 2 , Cycle 3, Cycle 4 , Cycle 5, Cycle 6, and Cycle 7 Dosing Day s 
(Weeks 5, 8, 11, 17, 23, and 29)  
9.3.1. Pre-dose  
Before dosing, the  following will be performed:  
â€¢ Physical examination (any areas related to the inclusion/exclusion criteria and body 
weight) and assessment of melanoma lesions  
â€¢ Vital signs  
â€¢ ECOG Performance Status  
â€¢ CBC  with differential and chemistry profile (including LFTs )  
â€¢ Complement ( CH50, C3, C4)  
â€¢ Coagulation tests  
â€¢ Thyroid function profile  
â€¢ Urinalysis with microscopic exam (Week s 8 and 17 only)  
â€¢ AEs 
â€¢ Concomitant medication monitoring  
â€¢ Radiological assessment (Week s 8, 17, and 29/EOT only)  
â€¢ Investigator assessment of response ( Week s 8, 17, and 29/EOT  only)  
â€¢ PK assessments ( see Table 3)  
â€¢ Immunogenicity assessments  (Weeks 5 , 11, 17, 23, and 29/EOT  only)  
â€¢ Blood biomarker assessments  (Week s 5, 8, and 2 9/EOT  only  during Phase 1 and 
Week 8 only during Phase 2)  
â€¢ The longest diameter of the injected tumor will also be assessed, when possible. 
â€¢ In Phase 2, all tumor biopsies are optional. See Section 13.2 and the Laboratory 
Manual for details on the collection of biopsies and analyses of biomarkers.  
â€¢ PRO using the EORTC QLQ -C30 (Weeks 8, 17, and 29/EOT only)  
9.3.2. Study Drug Admini stration  
â€¢ IMO -2125 by [CONTACT_707256]   
â€¢ Ipi[INVESTIGATOR_707133] i.v. infusion 
IMO -2125  Page 59 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960877]-dose  
â€¢ AEs 
â€¢ PK assessments ( Week 11 only; see Table 3)  
â€¢ Blood biomarker assessment  (Weeks 5, 8, and 29/EOT only during Phase  1) 
â€¢ ECG (Week 11 only;  [ADDRESS_960878] -dose IMO -2125 administration ) 
In addition, r adiological assessment ( computed tomography [ CT]) and Investigator assessment of 
response  will be conducted at Week 8 only (Â±7 days).  
9.4. Cycle 4 (Week 13)  
â€¢ Tumor biopsies by [CONTACT_707255] ( e.g., core or punch)  or FNA at Week 1 3 
(Cycle  4) are optional for both Phase 1 and Phase 2, and may occur with in a Â±3  day 
window  
9.5. Safety Follow -up Visit  ([ADDRESS_960879] Dose of IMO -2125 ) 
The following information will be captured at the Safety Follow -up (SFU) Visit ( 21 
days Â± [ADDRESS_960880] dose of IMO -2125) : 
â€¢ Physical examination (any areas related to the inclusion/exclusion criteria and body 
weight) and assessment of melanoma lesions  
â€¢ Vital signs  
â€¢ ECOG Performance Status  
â€¢ CBC  with differential and  chemistry profile (inc luding LFTs )  
â€¢ Complement ( CH50, C3, C4)  
â€¢ Coagulation tests  
â€¢ Thyroid function profile  
â€¢ Serum or  urine pregnancy test for WOCBP  
â€¢ Urinalysis with microscopic exam  
â€¢ ECG  
â€¢ AEs 
â€¢ Concomitant medication monitoring  
â€¢ PK assessments ( see Table 3)  
â€¢ Immunogenicity assessments  
IMO -2125  Page 60 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    9.6. Early Withdrawal  
Any patient may withdraw from the study at any time for any reason, without prejudice for his or 
her continued care. Also, an Investigator may withdraw a patient from the study in cases of 
noncompliance or if, for any reason , he or she feels it is in the patientâ€™s best interest.  
If a patient withdraws early , SFU Visit  procedures should be performed if possible. Reasons for 
withdr awal must be recorded.  
9.7. Unscheduled Visits 
Unscheduled visits and assessments may be conducted at Investigatorâ€™s discretion in response to 
new clinical observations or AEs. If performed, u nscheduled disease assessments will be 
recorded at an unscheduled vis it. Appropriate data from unscheduled visits should be recorded in 
the eCRF.  
IMO -2125  Page 61 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    10. STUDY TREATMENTS  
10.1. IMO -2125 
IMO -2125, a novel phosphorothioate oligodeoxynucleotide , is composed of two  strands of 
modified DNA joined at the 3â€™ ends. IMO -2125 is a hygroscopic whit e to off -white amorphous 
solid obtained by [CONTACT_27197]; it is highly soluble in aqueous media.  
IMO -2125 will be administered by [CONTACT_707257] (between 2 and 32 mg ; 
refer to Section  8.1).  
IMO -[ADDRESS_960881], each 5- mL glass vial contains IMO -2125 sodium 
salt equivalent to 25 mg/vial of IMO -[ADDRESS_960882] contains no 
excipi[INVESTIGATOR_707196] . For the aqueous sterile solution, each vial contains IMO -2125 
sodium salt equivalent to 8 mg/mL of IMO -2125 free acid compounded with 0.9% sodi um 
chloride.  
10.2. Ipi[INVESTIGATOR_707197].  
10.3. Pembrolizumab  
Pembrolizumab will be provided by [CONTACT_707258].  
10.4. Drug Handling and Administration  
10.4.1. Drug Delivery to Site  
After the research site has submitted all approved regulatory and study start -up documents, Idera 
Pharmaceuticals, Inc. will initiate a requisition for IMO -2125 to be delivered to the site via its 
distribution facility.  All IMO -2125 shipments are sent at 2Â°C  to 8Â°C . Upon receipt, the 
pharmacist or appropriate technician/designee must inspect the contents, verify temperature 
conditions, and confirm receipt of goods . Ipi[INVESTIGATOR_707198].  
Drug inventory will be maintained by [CONTACT_779]. The site must inform Idera Pharmaceuticals, Inc. , 
in writing, by [CONTACT_6972],  or e-mail of additional study drug needs at least 2 weeks  befo re the 
required receipt date.  
10.4.2. Drug Storage  
[IP_ADDRESS]. IMO -[ADDRESS_960883] are to be stored at 2Â°C to 8Â°C  and storage temperature must be 
continuously monitored. Instructions for reconstitution will be included in the Pharmacy Manual.  
IMO -[ADDRESS_960884] before preparation.  
IMO -2125  Page 62 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS]. Ipi[INVESTIGATOR_707199] 2Â°C to 8Â°C and protected from light (refer to the current  
Package Insert for more details) .  
[IP_ADDRESS]. Pembrolizumab Storage  
Vials of pembrolizumab are to be stored at 2Â°C to 8Â°C and protected from light (refer to the 
current Package Insert for more details).  
10.4.3. Administration  
[IP_ADDRESS]. IMO -2125 
IMO -2125 will be administered to each patient at one of five dose levels : 2, 4, 8, 16, or 32 mg . 
IMO -2125 will be  administered as a series of intratumoral injections administered as per  Table 4. 
Patients will remain at the study site for observation for a minimum of 30 minutes  following 
each administration of IMO -2125. A single tumor should be selected for injection throughout the 
study and designated as the â€œinjected tumorâ€ on the appropriate CRF.  
The injected tumor will be selected from (in order  of priority) pathologic draining lymph nodes, 
superficial or s.c. metastases, or deep (visceral) metastases, the latter requiring interventional 
radiology support. A separate (i.e., â€œnoninjectedâ€) tumor lesion should be identified as the distant 
lesion to  be biopsied  (optional in Phase 2)  and recorded on the CRF. Note that tumor biopsies 
should be done prior to study treatment administration. If a full dose can no longer be practically 
administered into the designated tumor for injection, another tumor may  be selected.  In the event 
that complete tumor regression occurs in all accessible lesions prior to completion of therapy, 
any remaining IMO -2125 doses should be administered into the tumor bed, except in the case of 
visceral lesions where remaining doses should be given s.c. to minimize procedural risks. 
The assigned dose of IMO -2125 will be administered into the â€œinjected tumorâ€ by [CONTACT_707259]. It is recommended that 
the tumors be injected with 25- gauge  needle; however, the choice of needle will be at the 
Investigatorâ€™s discretion. IMO -2125 should be thoroughly distributed within the injected tumor 
while avoiding necrotic areas, with a fanning method (spread the injection across several angles 
throughout the lesions, to maximize the IMO -2125  in the injected lesion) .  
The total injec ted dose should remain constant;  however , injection volume may need to be 
adjusted if the â€œinjected tumorâ€ decreases in size (see the Phar macy Manual for more details).  In 
the event a full dose can no longer be practically administered into the â€œinjected tumor ,â€ another 
lesion may be selected.  
[IP_ADDRESS]. Ipi[INVESTIGATOR_707200] (per the current Package Insert ) i.v. over 90 minutes at 3  mg/kg 
on Day [ADDRESS_960885] be administered within the Â±2  day study visit 
window . 
IMO -2125  Page 63 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS]. Dose Interruption for Ipi[INVESTIGATOR_125]- Related Toxicities  
A scheduled dose of ipi[INVESTIGATOR_707201] -mediated  adverse 
reactions or for symptomatic endocrinopathy. For patients with complete or partial resolution of 
AEs (Grade 0 -1), and who are receiving less than 7.5 mg prednisone or equivalent per day, 
ipi[INVESTIGATOR_707202] a dosage  of 3 mg/kg every [ADDRESS_960886] dose, whichever occurs earlier.  
Ipi[INVESTIGATOR_707203]:  
â€¢ Persistent moderate adverse reactions or inability to reduce corticosteroid dose  to 
7.5 mg prednisone or equivalent per day.  
â€¢ Failure to complete full treatment course within [ADDRESS_960887] 
dose. 
â€¢ Severe or life- threatening adverse reactions, including any of the following:  
âˆ’ Colitis with abdomin al pain, fever, ileus, or peritoneal signs; increase in stool 
frequency (7 or more over baseline), stool incontinence, need for i.v. hydration for 
more than 24 hours, gastrointestinal hemorrhage, and gastrointestinal perforation 
âˆ’ AST or ALT >5x the ULN or t otal bilirubin > 3x the ULN  
âˆ’ Stevens -Johnson syndrome, toxic epi[INVESTIGATOR_194], or rash complicated by 
[CONTACT_417], or necrotic, bullous, or hemorrhagic 
manifestations  
âˆ’ Severe motor or sensory neuropathy, Guillain- BarrÃ© syndrome, or myasthenia 
gravis  
âˆ’ Severe immune- mediated reactions involving any organ system (e.g., nephritis, 
pneumonitis, pancreatitis, non- infectious myocarditis)  
âˆ’ Immune -mediated ocular disease that is unresponsive to topi[INVESTIGATOR_707204] a patient experiences moderate enterocolitis, the Investigator should administer anti -diarrheal 
treatment, and if persistent for more than 1 week should initiate systemic corticosteroids at a 
dose of 0.5 mg/kg/day prednisone or equivalent and infliximab a ccording to institutional 
guidelines. Testing for latent tuberculosis (purified protein derivative skin test) is recommended.  
Mild to moderate dermatitis, such as localized rash and pruritis, should be treated 
symptomatically with administration of topi[INVESTIGATOR_707205] 1 week. 
The Investigator should administer corticosteroid eye drops to patients who develop uveitis, 
iritis, or epi[INVESTIGATOR_227]. Ipi[INVESTIGATOR_707206] -mediated 
ocular disease that is unresponsive to local immunosuppressive therapy.  
If patients need to discontinue ipi[INVESTIGATOR_707207] -related toxicities listed 
above, the Investigator may administer systemic corticosteroids at a dose  of 1 to 2 mg/kg/day of 
prednisone or equivalent. Upon improvement to Grade 1 or less, the Investigator should initiate 
IMO -2125  Page 64 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960888] institutional practices 
may also be implemented to treat these patients.  
[IP_ADDRESS]. Pembrolizumab  
Pembrolizumab will be administered (per the  current  Package Insert) i.v. over 30 minutes at 
200 mg on Day 1 of every 3 -week cycle, for a total of 4 doses , except in Cycle 1, where 
pembrolizumab will be administered on Day 8 . For patient s assigned to the 
IMO -2125 +  pembrolizumab arm, a t the discretion of the Investigator, after completing 
IMO -[ADDRESS_960889] be 
administered within the Â±2 day study visit window . 
Patients who initiated tre atment at the 2  mg/kg dose  may continue treatment using either the 
200 mg dose or the 2 mg/kg dose . If institutional practice requires certain patients to be treated 
using weight -based pembrolizumab dosing, those patients may be treated with the 2  mg/kg dose.  
[IP_ADDRESS]. Dose Interruption for Pembrolizumab -Related Toxicities  
Withhold pembrolizumab for any of the following:  
â€¢ Grade 2 pneumonitis  
â€¢ Grade 2 or 3 colitis  
â€¢ Grade 3 or 4 endocrinopathies  
â€¢ Grade 2 nephritis  
â€¢ AST or ALT > [ADDRESS_960890] or total bilirubin > 1.[ADDRESS_960891]  
â€¢ Any other severe or Grade 3 treatment -related adverse reaction  
Resume pembrolizumab in patients whose adverse reactions recover to Grade 0 -1. 
Permanently discontinue pembrolizumab for any of the following : 
â€¢ Any life -threatening adverse reaction (excluding endocrinopathies controlled with 
hormone replacement therapy)  
â€¢ Grade 3 or 4 pneumonitis or recurrent pneumonitis of Grade 2 severity  
â€¢ Grade 3 or 4 nephritis  
â€¢ AST or ALT > [ADDRESS_960892] or total bilirubin > [ADDRESS_960893]; for patients with liver metastasis 
who begin treatment with Grade [ADDRESS_960894] or ALT increases by â‰¥ 50% 
relative to baseline and lasts for at least 1  week  
â€¢ Grade 3 or 4 infusion- related reactions  
â€¢ Inability to reduce corticosteroid dose  to 10 m g or less of prednisone or equivalent per 
day within 12 weeks  
IMO -2125  Page 65 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    â€¢ Persistent Grade 2 or 3 adverse reactions (excluding endocrinopathies controlled with 
hormone replacement therapy) that do not recover to Grade 0- [ADDRESS_960895] 
dose of pembrolizum ab 
â€¢ Any severe or Grade 3 treatment -related adverse reaction that recurs  
[IP_ADDRESS]. Supportive Care Guidelines for Hypophysitis  
Refer to the prescribing information for ipi[INVESTIGATOR_707208]. 
Patients should be monitored for signs and symptoms of hypophysitis such as adrenal 
insufficiency, hyperthyroidism, or hypothyroidism. 
Patients being treated with ipi[INVESTIGATOR_707209] . Treatment with corticosteroids at a dose of 1 to 2 m g/kg/day of 
prednisone or equivalent should be initiated along with appropriate hormone replacement 
therapy . Consider a referral to an endocrinologist . Ipi[INVESTIGATOR_707210] â‰¤1 and decrease of the corticosteroid dose  to <7.5 mg/day prednisone or 
equivalent . Ipi[INVESTIGATOR_707211] 
â‰¥6 weeks or inability to reduce the corticosteroid dose to <7.5 mg/day prednisone or equivalent.  
Patients being treated with pembrolizumab should have treatment withheld for hypophysitis 
Grade â‰¥[ADDRESS_960896] . Pembrolizumab treatment may be resumed 
after resolut ion to Grade â‰¤1. Pembrolizumab should be permanently discontinued for 
life-threatening hypophysitis not controlled with hormone replacement therapy, inability to 
decrease corticosteroid dose to <10 mg/day prednisone or equivalent within [ADDRESS_960897] R esearch Organization (CRO)  will provide 
drug accountability logs, a pharmacy binder , and other study drug preparation worksheets, as 
necessary . Each vial of IMO -[ADDRESS_960898] be assessed according to the guidelines described in that section to determine 
continued dosing (refer to Section  8.1.5) . 
IMO -2125  Page 66 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960899] received an inadequate exposure to study drug relative to his or her 
planned dose level for non- study drug related reasons, he or she will be considered for 
replacement in the s tudy, after discussion between Investigators, the site , and Idera 
Pharmaceuticals, Inc. If inadequate exposure to study drug is due to toxicity, this wil l be taken 
into account in the evaluation of DLT for that dose level (see Section  8.1.3 ). 
10.6.2. Discontinuation of Study Drug  
The study drug will be discontinued in any patient who is unable to tolerate it as evidenced by 
[CONTACT_707260][INVESTIGATOR_58341]. 
10.7. Concomitant and Prohibited Medications  
10.7.1. Concomitant Medications  
With the exception of the prohibited drugs listed in Section  10.7.2, concomitant prescription 
drugs  and over -the-counter drugs are permitted. These should be recorded on the e CRF  starting 
with medications taken 30 days before the patient signs the informed consent form (ICF) . 
10.7.2. Prohibited Medications  
The following drugs are prohibited while the patient is in this study :  
â€¢ Anti-cancer therapi[INVESTIGATOR_707212]  
â€¢ Drugs that either stimulate  or suppress the immune system:  
âˆ’ Systemic steroid therapy higher than physiologic dose  (>7.5 mg/day of 
prednisone  or equivalent ) 
Note:  For patients with pre -existing  endocrine insufficiency, stress doses of 
replacement steroid treatment may be given on the day of and the day after study 
treatment administration (i.e. , dosing with IMO -2125, ipi[INVESTIGATOR_125], or 
pembrolizumab). Additional need for steroid replacement should be discussed 
with the Medical Mon itor. 
âˆ’ Topi[INVESTIGATOR_707213]  
âˆ’ Live vaccines (attenuated vaccines are permitted)  
â€¢ Experimental v accines  
â€¢ Investigational/experimental medicines  
IMO -2125  Page 67 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    11. ADVERSE EVENT REPORT ING  
11.1. Adverse Events  
Adverse events should be assessed continuously throughout the study and recorded on the eCRF . 
Reporting during the follow -up phase of the study should be limited to Grade â‰¥3 AEs, associated 
concomitant medications, and serious adverse events ( SAEs ; see Table 1 and Table 2).  
11.1.1. Definition of Adverse Events  
[IP_ADDRESS]. Adverse Event  
An AE is any untoward medical occurrence temporally associated with the use of a medical 
product in a patient, whether or not  the event is conside red causally related to the medical 
product.1 An AE can be a new occurrence or an existing process that increases significantly in 
intensity or frequency .  
[IP_ADDRESS]. Serious Adverse Event  
An AE is serious  when the patient outcome is one or more of the following:  
â€¢ Death.  
â€¢ Life-threatening, meaning that the patient was at immediate risk of death from the 
event at the time that the event occurred . It does not include an event which 
hypothetically might have caused death if it occurred in a more severe form.  
â€¢ Hospi[INVESTIGATOR_059], initial or prolonged, meaning that a hospi[INVESTIGATOR_26179]/or 
prolongation of a hospi[INVESTIGATOR_58360], or occurred 
as a consequence of the event . It does not include a pre -planned elective hospi[INVESTIGATOR_707214], or, in general, a hospi[INVESTIGATOR_58362] 24 hours duration.  
â€¢ Disability or incapacity that is persistent or significant.  
â€¢ Congenital anomaly or birth defect.  
â€¢ Important medical event  that, although not immediately  life-threatening, requires 
intervention in order to prevent one of the other serious outcomes listed above . 
Examples of such events are allergic bronchospasm requiring intensive treatment in 
an emergency room or at home; blood dyscra sias or convulsions that do not result in 
hospi[INVESTIGATOR_059]; or the development of drug dependency or drug abuse.  
                                                 
[ADDRESS_960900] in this protocol will hereafter be referred to as study drug (synonym: investigational agent).   
IMO -2125  Page 68 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS]. Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  
A S[LOCATION_003]R is defined as an SAE that meets both  the following criteria with respect to study drug:  
â€¢ Suspected  â€” is assessed as related or possibly related to study drug (see 
Section  [IP_ADDRESS]);  
â€¢ Unexpected  â€” compared to the study drug -related AEs described in the 
Investigatorâ€™s Brochure, the event meets any  of the following criteria:  
âˆ’ The event was not previously described;  
âˆ’ The event is now characterized as more severe (see Section [IP_ADDRESS]);  
âˆ’ The event is now characterized more specifically (e.g., an event of â€œinterstitial 
nephritisâ€ in a patient receiving an agent previously described as associated with 
â€œacute renal failureâ€).  
In clinical trials involvin g ill patients, events considered related to the natural history of the 
disease under study or to lack of efficacy (that is, the event is considered more likely related to 
those factors than to other factors, including study drug) are not considered "unexpected."  Lack 
of efficacy is recorded as specified elsewhere in the Protocol.  
11.1.2. Recording Adverse Events  
Procedures for the collection and recording of AEs are as follows:  
â€¢ From obtaining informed consent through the SFU  Visit, there will be active 
surveillance to identify all AEs. Events will be recorded in the AE portion of the 
electronic data capture ( EDC ), with particular attention to whether the onset of the 
event was before or after the administration of the first dose of study drug . All 
recorded event s will be included in applicable line listings, but only events with onset 
after administration of the first dose will be included in summaries of 
treatment -emergent AEs .  
â€¢ After the end of study, surveillance will be passive (only events brought to the 
Investigatorâ€™s attention will be considered) and only events assessed as S[LOCATION_003]Rs will 
be recorded (see Section  [IP_ADDRESS]).  
â€¢ In accordance with the FDA gu idance document â€“ Safety Reporting Requirements for 
Investigational New Drugs (INDs) and Bioavailability/Bioequivalence (BA/BE) 
Studies â€“ disease progression does not require reporting as an AE or SAE. However, 
signs and symptoms related to disease may be reported at the discretion of the 
Investigator.  
11.1.3. Characterizing Adverse Events  
For each AE recorded the following characteristics will be noted .  
[IP_ADDRESS]. Description of Event  
The diagnosis or description will be as specific and complete as possible (i.e., â€œlower extremity 
edema,â€ rather than just â€œedemaâ€) . Whenever possible, signs and symptoms due to a common 
IMO -2125  Page 69 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    etiology will be reported as an integrated diagnosis; for example, cough, runny nose, sneezing, 
sore throat and head congestion would be reported as â€œupper r espi[INVESTIGATOR_4416].â€  
[IP_ADDRESS]. Date and Time of Onset  
The date and time at which the event was first apparent  will be recorded, if known. The time of 
onset of symptoms may be appreciably earlier than the date and time the Investigator becomes 
aware of the event. Some events may be apparent to the patient and Investigator independently, 
and information from each may contribute to the final report. For example, a patient may report 
the onset of a rash two days prior to  being seen by a physician who makes a diagnosis  of herpes 
zoster based on appearance and laboratory confirmation. In that case, there is a single AE, with 
the date of onset based on the date of the initial observation by [CONTACT_5363] a specific 
description (herpes zoster) based on the clinical exam and tests .     
[IP_ADDRESS]. Relationship to Study Drug  
This determination is based on the Investigatorâ€™s clinical judgment regarding the likelihood that 
the study drug caused the AE and may include consideration of some or all of the following 
factors:  
â€¢ Alternative pos sible causes of the AE, including the patientâ€™s underlying disease or 
co-morbid conditions, other drugs, other host and environmental factors.  
â€¢ Temporal sequence between the exposure to study drug and the AE.  
â€¢ Whether the clinical or laboratory manifestatio ns of the AE are consistent with known 
actions or toxicity of the study drug.  
â€¢ Whether the AE resolved or improved with decreasing the dose level or stoppi[INVESTIGATOR_35620] (i.e., dechallenge); or recurred or worsened with re -exposure to the drug 
(i.e., re challenge).  
The relationship between the study drug and the AE will be described using one of the following 
categories:  
â€¢ Related â€” the study drug is more likely the cau se of the AE than other factors.  
â€¢ Possibly related  â€” there is a reasonable possibility that the study drug is the cause of 
the AE, including that the study drug and another factor(s) are equa lly likely as 
causes of the AE.  
â€¢ Unlikely related  â€” another factor is considered more likely  the cause of the AE than 
the study drug.  
â€¢ Not related  â€” another factor is considered to be the cause of the AE.  
Related and possibly related AEs may result during the use of the study drug as planned (per 
protocol), or from abuse, withdrawal or over -dosage of the agent.  
IMO -2125  Page 70 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS]. Immune -related Adverse Events  
The following list of AEs, which have been associated with the use of immunotherapy agents, 
will be considered to be immune -related and should be considered as such unless another 
etiology can be clearly established:  
â€¢ Adrenal insufficiency  
â€¢ Hypophysitis  
â€¢ Hypopi[INVESTIGATOR_297]  
â€¢ Other endocrinopathies  
â€¢ Colitis  
â€¢ Enterocolitis  
â€¢ Dermatitis CTCAE Grade â‰¥3  
â€¢ Autoimmune dermatitis CTCAE Grade â‰¥3  
â€¢ Guillain Barre syndrome  
â€¢ Hepatitis  
â€¢ Myasthenia gravis  
â€¢ Pneumonitis  
â€¢ Stevens Johnson Syndrome  
â€¢ Toxic epi[INVESTIGATOR_194]  
â€¢ Uveitis  
â€¢ Iritis  
â€¢ Any AEs that the Investigator considers to be of autoimmune or immune -related 
origin (those AE terms designated as such in the eCRF).  
Immune -related AEs will be summarized in the clinical study report.  
[IP_ADDRESS]. Severity  
The severity of clinical AEs (i.e., symptoms reported by [CONTACT_5363]/or signs observed by [CONTACT_3786]) will be assessed using the guidelines summarized in Table 7 based on CTCAE 
v4.03 criteria.  
Table  7:  Estimating Severity Grade  
Grade 1/Mild  Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated  
Grade 2/Moderate  Minimal, local, or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living1 
Grade 3/Severe  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; 
limiting self -care activities of daily livin g2 
Grade 4/Life -threatening  Life-threatening consequences; urgent intervention indicated  
Grade 5/Death  Death related to adverse event  
1. Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_3112], using t he 
telep hone, managing money, e tc. 
2. Self -care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.  
IMO -2125  Page 71 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS]. Grading of Laboratory Safety Tests for Reporting and Analysis  
Treatment -emergent abnormal laboratory results will be handled as follows:  
â€¢ Graded using NCI -CTCAE Version 4.03 criteria  
â€¢ Assessed as potential DLT events based on pre -specified criteria (see Section  8.1.5)  
â€¢ Reported as AEs when assessed as clinically significant ( â€œCSâ€)  using the procedures 
and criteria detailed in Section  11.1.2. 
[IP_ADDRESS]. Management of Study Drug upon Occurrence of an Adverse Event  
For each AE the Investigator will indicate which one of the following actions regarding the 
administration of study drug was taken because of that AE:  
â€¢ Discontinued  â€” study drug was stopped permanently due to the AE.  
â€¢ Dosing Interrupted  â€” study drug regimen was modified by [CONTACT_139670], 
i.e., 1 or more doses were not administered, but drug was not stopped permanently.  
â€¢ Dose Decreased  â€” study dr ug regimen was modified by [CONTACT_58413], i.e., by 
[CONTACT_139671], strength or amount. 
â€¢ None  â€” no change in the administration of study mediation.  
For patients whose treatment is paused and then resumed at a lower dose level due to events such 
as DLTs (see Section  8.1.5), the management of study drug will be recorded as â€œDose 
Decreased.â€  
[IP_ADDRESS]. Actions Taken for Management of Adverse Event  
Adverse ev ents will be followed and managed by [CONTACT_737], including obtaining any 
supplemental studies needed to define the nature and/or cause of the event (e.g., laboratory tests, 
diagnostic procedures, consultation with other health care professionals).  
For each AE the Investigator will categorize as follows the actions taken to manage the AE:  
â€¢ Concomitant medication â€” one  or more medications (prescription or 
over-the-counter) were started or increased in dose; non- medication actions may also 
have been ordered.  
â€¢ Other action â€” only  non- medication action(s) were ordered as management of the 
AE (e.g., bed placed in Trendelenburg position, warm compresses applied to access 
site).  
â€¢ No action â€” no actions were ordered for management of the AE.  
[IP_ADDRESS]. Follow-up and Outcome of Adverse Events  
If possible, AEs will be followed until resolved (synonyms: recovered, recuperated, ended) either 
with or without sequelae, including for patients who prematurely discontinue study participation. 
For AEs that are asses sed as not drug- related and are not resolved at the end -of-study visit, 
follow -up may be limited with the approval of the Medical Monitor.  
IMO -2125  Page 72 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    The outcome of each event will be described using the following categories:  
â€¢ Resolved without sequelae â€” the event r esolved and patient returned to baseline.  
â€¢ Resolved with sequelae â€” the event resolved but the patient is left with residual 
problems (e.g., functional deficits, pain).  
â€¢ Resolving  â€” at the last observation, the event was improving.  
â€¢ Not Resolved  â€” at the l ast observation, the event was unchanged.  
â€¢ Death  (Fatal)  â€” to be used for the one  AE which, in the judgment of the 
Investigator, was the primary  cause of death.  
â€¢ Unknown  â€” there were no observations after the onset (initial observation or report) 
of the ev ent.  
Note: Resolving and Not Resolved may also be used for AEs that were unresolved at the time a 
patient died, but were not  assessed as the primary cause of death.  
[IP_ADDRESS]. Date and Time of Outcome  
For each class of outcome as defined above,  Table  8 indicates the date and time to be recorded. 
As discussed in detail for date/time of onset (see Section  [IP_ADDRESS]), determining the date/time an 
event resolved (ended) should reflect the type of event and the source of the information.  
Table  8: Date and Time of Outcome for Adverse Event by [CONTACT_707261] (with or without sequelae)  Date and time event observed or reported as resolved  
Death  Date and time of death  
Resolving or Not Resolved  Date and time of last observation  
Unknown  None (see definition above)  
11.1.4. Reporting Adverse Events  
[IP_ADDRESS]. Where to Report Serious Adverse Events  
Serious AE reporting will be performed by [CONTACT_707262]; detailed training will 
be provided during site initiation . Reports and supporting materials relating to SAEs will be 
scanned and uploaded into the EDC system . Contact [CONTACT_707263]. 
In the event an SAE cannot be submitted via EDC, contact [CONTACT_707264].  
IMO -2125  Page 73 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    [IP_ADDRESS]. Procedures for Reporting Serious Adverse Events to the Sponsor  
The initial notification  of each SAE will be entered into the EDC system within 24 hours  of the 
time the Investigator (or the Investigator's designee) becomes aware that the event has occurred . 
The following items will be entered into the appropriate EDC sec tion (any items not available 
should be explicitly noted):  
â€¢ Protocol number, study site, patient number.  
â€¢ Investigatorâ€™s name [CONTACT_3669] [CONTACT_3031] (phone, email).  
â€¢ Description of the event (i.e., date and time of onset, initial assessment, treatments 
and course).  
â€¢ Current status of the patient and the event.  
â€¢ Criteria by [CONTACT_58418].  
â€¢ Date of the first injection of study drug.  
â€¢ Date of the last injection of study drug prior to the event.  
â€¢ Assessment of relationship of study drug to the event.  
â€¢ Whether the study drug was discontinued or adjusted as a result of the event.  
The following  additional information will be entered within 2 days for death and life -threatening 
events and wi thin 4 day s for all other SAEs:  
â€¢ Narrative summary of the event â€” to include specific information that will assist in 
understanding the event, e.g., relevant medical history, co -morbid conditions, 
physical exam, diagnostics, assessment, treatments (including concomitant 
medications), response to treatment, course, and outcome (if known);  
â€¢ Copi[INVESTIGATOR_58365] â€” including diagnostic procedures 
(e.g.,  laboratory, ECG, x -ray), surgical procedures, and consultations.  
Additional documentation may be submitted  as part of a follow -up report.  
[IP_ADDRESS]. Other Reportable Events  
Certain events that occur in the absence of an AE should be reported to the Sponsor. These 
include the following:  
â€¢ Pregnancy exposure (patient becomes pregnant while taking study drug). Should a 
female patient or partner of a male patient become pregnant during the study, the 
patient will inform the Investigator. The patient will be asked to follow up with the 
study site to report the eventual outcome of the pregnancy. The information will be 
tracked by  [CONTACT_1034].  
â€¢ Lactation exposure (patient was taking study drug while nursing an infant).  
â€¢ Accidental exposure (someone other than the patient was exposed to study drug).  
â€¢ Overdose (patient received more than the prescribed dose of study drug within a 
given timeframe).  
IMO -2125  Page 74 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    â€¢ Other medication errors that potentially place patients at greater risk of harm than was 
previously known or recognized (e.g., study drug was administered via incorrect 
route).  
[IP_ADDRESS]. Requirements for Expedited and Periodic Reporting of Adverse Events  
Suspected unexpected serious adverse reactions are required to be reported rapi[INVESTIGATOR_58366] /ECs  (typi[INVESTIGATOR_16195] 7 days for fatal or life -threatening S[LOCATION_003]Rs; within 
15 days for all other S[LOCATION_003]Rs) . The Sponsor and the Invest igator will work together to meet 
these reporting requirements.  
 
IMO -2125  Page 75 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    12. SAFETY ASSESSMENTS  
12.1. Vital Signs 
Vital sign measurements will be taken at intervals as specified in the Schedules  of Evaluations 
(Table 1 and Table 2) and Section  9. Where feasible, vital signs should be measured before 
having blood drawn for laboratory evaluations. Blood pressure measurements should be taken 
with the patient in a sitting position, preferably for approxim ately 5  minutes .  
12.2. Laboratory Assessments  
Instructions for conducting laboratory assessments and processing samples will be provided in a 
study manual to the study staff before study initiation. Laboratory tests will be performed at 
intervals as specified i n the Schedule s of Evaluations ( Table 1 and Table 2 ) and Section  9. Blood 
and urine samples will be analyzed for the analytes presented in Table 9.  
IMO -2125  Page 76 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Table  9: Laboratory Measurements  
Hematology  Chemistry  Urinalysis (Dipstick)  Other  
Basophils  Albumin  Glucose  Thyroid Profile  
Eosinophils  Alkaline phosphatase  pH TSH  
Lymphocytes  ALT  Leukocytes  Free thyroxine (free T4)  
Atypi[INVESTIGATOR_707215] 
(total or free T3)  
Monocytes  Total bilirubin  Urobilinogen   
Neutrophils  BUN Protein  Coagulation  
Hematocrit  Creatinine  Occult blood  PT 
Hemoglobin Calcium  Specific gravity  aPTT  
MCH  CO 2 Ketones  INR 
MCHC  Sodium, chloride, and 
potassium  Bilirubin   
MCV  Cholesterol   Complement  
Platelet count  GGT  Microscopy  CH50  
RBC count  Glucose  Bacteria  C3 
WBC count  Lactate dehydrogenase  Crystals  C4 
 Phosphate  Casts (cellular, granular, and 
hyaline)   
 Total protein  RBC   
 Triglycerides  WBC   
 Uric acid  Epi[INVESTIGATOR_1663]   
 Î²hCG for WOCBP    
Î²hCG=beta human chorionic gonadotropin; ALT=alanine aminotransferase; aPTT= activated partial thromboplastin 
time; AST=aspartate aminotransferase; BUN=blood urea nitrogen; C3=complement component 3; 
C4=complement component 4; CH50=total complement activity 50; GGT=gamma glutamyltra nsferase; 
INR=international normalized ratio; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin 
concentration; MCV=mean corpuscular volume; PT=prothrombin time; RBC=red blood cell; TSH=thyroid -
stimulating hormone; WBC=white blood cell; WOCB P=women of childbearing potential  
12.3. Other Safety Assessments  
12.3.1. Physical Examination  
A medical history will be taken at the Screening Visit. A physical examination (including special 
attention to each of the inclusion and exclusion criteria in the protocol) and assessments of 
melanoma lesions will be performed as outlined in the Schedule s of Evaluations ( Table 1 and 
Table 2).  
Patient height will be recorded at the Screening Visit only.  
IMO -2125  Page 77 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    12.3.2. Electrocardiogram Monitoring  
A resting 12 -lead ECG will be performed at intervals as specified in the Schedules  of 
Evaluations ( Table 1 and Table 2) and Section  9.  
12.3.3. ECOG Performance Status  
The patientâ€™s ECOG performance status will be evaluated per guidance in Section  21.1 as 
outlined in the Schedule s of Evaluations ( Table 1 and Table 2).  
IMO -2125  Page 78 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    13. PHARMACOKINETICS AND IMMUN E RESPONSE  
The t iming of sample collection is provided in the Schedule s of Evaluations ( Table 1 and 
Table 2) and the Schedule of PK Blood Sampling ( Table 3). Detailed instructions and materials 
for all blood sampling will be provided in a separate study manual and kits.  
13.1. Pharmacokinetic Assessments  
The plasma PK of single -dose IMO -2125 and the PK of repeat -dose IMO -2125 administered by 
[CONTACT_707238][INVESTIGATOR_707216]. The following parameters will be determined for IMO -2125 plasma PK , 
if appropriate : 
â€¢ Maximum plasma concentration (C max) 
â€¢ Time of C max (tmax) 
â€¢ Area under the curve from [ADDRESS_960901] measurable plasma concentration (AUC 0-t) 
Serum concentrations of ipi[INVESTIGATOR_707153] 2, 5, 8, 11, 
17, and 23. For patients who continue pembrolizumab treatment, pembrolizumab pre -dose PK 
samples should be collected before dosing at all visits. A post -dose pembrolizumab PK sample 
should be collected [ADDRESS_960902] 20 patients  treated at the IMO -2125 RP2D after which the Sponsor will determine if 
additional samples are needed.  The Sponsor will then inform the Investigators whether or not to 
continue collecting plasma concentration samples.  
The relationship between PK assessments, safety, efficacy, and pharmacodynamics variables will 
be explored whenever possible. 
13.2. Pharmacodynamic Markers of Immune Response  
For Phase 1, biopsies of the injected tumor will be performed at the Screening Visit (within 
[ADDRESS_960903] treatment); within 24 to 48 hours after IMO -2125 injection on Week 1 
(Cycle  1); Week  2 (Cycle 1; optional) ; during Week 8 (Cycle 3) ; and opt ionally  at Week 13 
(Cycle 4) and  at the time of disease progression or during Week 23, whichever is later. Tumor 
biopsies of the designated non- injected lesion will be performed at Screening , prior to the first 
dose of ipi[INVESTIGATOR_707133] (optional ), and during Week 8. For Phase 2, tumor 
biopsies are optional at all specified visits.  Surgical methods (e.g., punch or core) are preferred 
over FNA where feasible.  
For those patients who have liver or other visceral metastases injected with IMO -2125, rep eat 
biopsy of liver or other visceral tumor lesions may not always be possible. Therefore, repeat 
biopsies will be performed only when feasible in these patients . Note that tumor biopsies should 
be done prior to study treatment administration. 
The Week 8 ( Cycle 3) and Week 13 (Cycle 4) biopsies may be performed within a Â±3  day 
window. If tumor response is observed early during initial treatment, the Week 8 biops ies may 
IMO -2125  Page 79 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960904] -treatment and may include , but 
are not limited to:  
â€¢ Biomarkers (CD8+ T  cells, NK cells, pDC/myeloid DC, memory T  cells in tumor tissue, 
T cells, and cytokine levels in blood)  
â€¢ Any potential association between these biomarkers and antitumor activity  
â€¢ Gene profiling (with RNA and DNA extraction)  
â€¢ Immunogenicity (antibodies to IMO -2125, ip ilimumab , or pembrolizumab)  
13.2.1. Immunogeni city Analyses  
Exploratory  analyses will include assessing the occurrence of antibodies to the administered 
oligonucleotide  (anti -IMO -2125 antibodies) , as well as antibodies to the administered 
ipi[INVESTIGATOR_707217] (refer to Table 1 and Table 2).  
13.2.2. Immunologic Evaluations  
Immunologic evaluations will include , but not be limited to : 
â€¢ Immunophenot ypi[INVESTIGATOR_707218]  (on biopsies from patients enrolled in the 
Phase 1 portion) ;  
â€¢ The assessment of TCR VÃŸ CDR3 clonal diversity will be done using ImmunoSeqâ„¢ 
(Adaptive Biotechnologies, Seattle, WA) ;  
â€¢ NanoString gene expression analyses.  
IMO -2125  Page 80 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    14. ASSESSMENT OF EFFICACY  
14.1. Tumor Response  
Tumor response will be assessed using immune -related response criteria ( irRC ) and 
RECIST  v1.[ADDRESS_960905] v1.1 in Phase 2 ( Section  21.2, 
Section  21.4, and Section  21.3,  respectively). Efficacy evaluation should include clinical 
examination and CT or magnetic resonance imaging scanning of known sites of disease. 
Ultrasound studies performed for needle biopsy localiz ation or IMO -2125 dosing should not be 
used to assess tumor status (in accordance with RECIST  v1.1). The same method(s) of 
assessment should be used throughout the study for consistency wherever feasible. Response 
should be assessed at Weeks 8, 17, and [ADDRESS_960906] every 3 months thereafter until 
progression or start of a new anti -cancer therapy (see Section  8.2.2). Response assessments of 
CR, PR, a nd progressive disease must be confirmed by [CONTACT_9661] â‰¥4 weeks after the initial 
documentation of response. 
IMO -2125  Page 81 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    15. ASSESSMENT OF PATIENT REPORTED OUTCOMES 
15.1. EORTC QLQ-C30 
The EORTC QLQ -C30 is an integrated system for assessing the health -related qualit y of life 
(QoL)  of cancer patients participating in inte rnational clinical trials. The EORTC has adopted a 
modular approach to QoL assessment, consisting of a core questionnaire to be administered, if 
necessary with a module specific to tumor site, treatment modality, or  a QoL dimension 
(Aaronson, 1993).  
The EORTC QLQ -C30 is the product of more than a dec ade of collaborative research. It is a 
questionnaire for patient self -completion, composed of multi -item and single -item measures . 
These include 5 functional scales (phys ical, role, emotional, social, and cognitive), 3 symptom 
scales (fatigue, nausea and vomiting, and pa in) and a global health status/QoL scale, and 6 single 
items (dyspn ea, insomnia, appe tite loss, constipation, diarrhea, and financial difficulties) 
(Aarons on, 1993).  
All of the scales and single -item measures  range in score from 0 to 100. A high scale score 
repre sents a higher response level. Thus, a high score for a functional scale represents a 
high/ healthy level of functioning, a high score  for the global  health status/QoL represents a high 
QoL, but a  high score for a symptom scale /item represents a high level of 
symptomatology /problems. 
The EORTC QLQ -C30 will be administered to all subjects according to the Schedule of 
Evaluations ( Table 1 and Table 2). To minimize bias in the PRO data, the PRO assessments 
should be completed before study drug administration and AE assessments. 
 
 
IMO -2125  Page 82 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    16. STATISTIC AL ANALYSIS METHODS 
Please refer to Section  8.1.3 for the rules around dose level escalation and stoppi[INVESTIGATOR_007].  
16.1. Determination  of Sample Size  
The primary objective of Phase 2 is to assess the preliminary clinical activity , defined as the 
investiga tor-assessed ORR, of IMO -2125 in combination with ipi[INVESTIGATOR_707158] -2125 in 
combination with  pembrolizumab in patients with progression on or following PD -(L)1 inhibitor  
therapy for metastatic melanoma. Given that two primary hypotheses are being tested  (regarding 
the ORR of IMO -2125 and ipi[INVESTIGATOR_707159] -2125 and pembr olizumab), a 
Bonferroni correction has been applied to the alpha to control the  Type I error  rate for the trial . 
Assuming the ORR for patients who receive ipi[INVESTIGATOR_707160] 11% (the historical 
response rate in patients who are PD -1 inhibitor naÃ¯ve), and a target  ORR of 35% for patients 
who receive  the IMO -2125 + ipi[INVESTIGATOR_707161], a  sample size of 21 patients 
would achieve 77 % power to detect a 24% diff erence in response rates using a one -sided 
significance level of 2.5%.   
The IMO -2125 + ipi[INVESTIGATOR_707162] a two -stage design with a targeted Type I 
error rate of 0.[ADDRESS_960907] the alternative of at leas t 35% . 
With this method, [ADDRESS_960908] v1.1 response, then the null hypothesis H o will be rejected in favor of 
the alternative H a. In this treatment arm, this design has statistical power of 77%, an expected 
sample size of 13.[ADDRESS_960909] stage of 69.7% if the response proportion is â‰¤0.11.  
At least 60  patients  may be enrolled in this arm , including the 21 ipi[INVESTIGATOR_125] -naÃ¯ve  patients who  
will be used to tes t the null hypothesis . These 60 patients will include those with primary 
exposure to ipi[INVESTIGATOR_125] . The purpose of treating ~[ADDRESS_960910]  is to improve the precision of the ORR estimate in the primary efficac y 
population and to allow preliminary assessment of safety and preliminary efficacy in the 
population with prior exposure to ipi[INVESTIGATOR_125]. The 95% exact confidence intervals for a range of 
sample sizes for an ORR of at least 0.35 is in Table 10. 
Table  10: ORR and Confidence Intervals with an ORR of At Least  0.35 for Possible Sample 
Sizes  
n=21  n=30  n=35  n=40  n=45  
0.381  
( 0.1811, 0.6156)  0.367  
(0.1993 , 0.5614)  0.371  
(0.2147, 0.5508  0.375  
(0.2273 , 0.5420)  0.356  
(0.2187, 0.5122)  
Assuming a RECIST v1.[ADDRESS_960911] 5%, and a target  ORR f or patients who receive the 
IMO -2125 +  pembrolizumab combination treatment of 35%, a sample size of 
IMO -2125  Page 83 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    21 efficacy -evaluable patients would achieve 96 % power to detect a 30% difference in response 
rates using a one -sided significance level of 2.5%.  
The IMO -2125 + pembrolizumab treatment arm will use a two -stage design with a targeted 
Type  I error rate of 0.[ADDRESS_960912] 35% . If at 
least [ADDRESS_960913] v1.1 
response, then the null hypothesis H o will be rejected in favor of the alternative H a. In this 
treatment arm, this design has statistical power of 96%, an expected sample size of 14.41, and a 
probability of stoppi[INVESTIGATOR_707163] 60% if the response proportion is â‰¤0.05. 
16.2. Analysis Populations  
â€¢ Primary Ipi[INVESTIGATOR_125]  + IMO -2125 Efficacy Evaluable (PI[INVESTIGATOR_707155]) Population:  all patients 
who are ipi[INVESTIGATOR_125] -naÃ¯ve on study entry (including those who received ipi[INVESTIGATOR_707219]) and who are treated at the RP2D for the IMO -2125 + 
ipi[INVESTIGATOR_43809] , regardless of wh ich p hase of the study they receive it; and 
who received at least one dose of each study drug.  
â€¢ Secondary Ipi[INVESTIGATOR_125] +  IMO -2125 Efficacy Evaluable (SIIEE) Population:  all 
patients who are not ipi[INVESTIGATOR_125] -naÃ¯ve on study entry and who are treated at the 
RP2D for the IMO -2125 + ipi[INVESTIGATOR_43809], regardless of which phase of the 
study they receive it ; and who received at least one dose of each study drug. 
â€¢ Primary Pembrolizumab  + IMO -2125 Efficacy Evaluable (PPI[CONTACT_232200]) Population:  all 
patients who are treated at the RP2D for the IMO -2125 + pembrolizumab 
combination, regardless of which phase of the study they receive it;  and who received 
at least one dose of each study drug.  
â€¢ Safety  Population: all patients who received at least one dose of IMO -2125 .  
â€¢ DLT Evaluable Population: all patients in the Safety Population who continue 
participation in the study for the entire DLT evaluation period, or who discontinue 
prematurely due to a DLT.  
â€¢ PK Population: All subjects in the Safety Population who have â‰¥[ADDRESS_960914] 
deviation, median, and range. Categorical variables will be summarized by [CONTACT_707241], 
and if spec ified, with 95% confidence intervals  for the proportion. Missing data will not be 
imputed  except as described in the Statistical Analysis Plan . 
Data will be analyzed at the end of dose -finding for each treatment . Phase 2 data will be 
analyzed at the end of  Phase 2 ( approximately  [ADDRESS_960915] patient in Phase 2 has 
commenced study treatment ). 
IMO -2125  Page 84 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    16.4. Analysis of Safety  
Analysis of DLTs will be performed on the DLT Evaluable Population. All other safety analyses 
will be performed on the Safety Population.  
Dose-limiting toxicities will be summarized by [CONTACT_707265] n and percent age.  
Vital signs, laboratory values, and ECG values will be summarized descriptively; no formal 
statistical hypotheses will be tested .  
For laboratory values that are continuous, shift tables from baseline to worst value on study will 
be produced. Laboratory values that are out of the normal range as graded by [CONTACT_707266], and any values that are judged by [CONTACT_707267].  
Adverse events will be tabulated by [CONTACT_61121] . Adverse 
event  tables will b e produced by [CONTACT_1570]. Adverse event  summaries will be as follows: 
overall, by [CONTACT_926], and relate d AEs.  Listings of any deaths, SAEs , and AEs leading to 
discontinuation of treatment will be produced.  
Any abnormal findings from physical examinations will be reported as AEs. As such, physical 
examination results will not be summarized.  
Concomitant medic ations will be coded by [CONTACT_707268] . The ECOG performance status will 
be tabulated by [CONTACT_21751]. 
16.5. Analysis of Pharmacokinetics  
For each cohort, the plas ma IMO -2125 concentration data will be analyzed by 
[CONTACT_105]-compartmental PK analysis. Descriptive statistics will be provided for concentration data 
and all PK assessment  values by [CONTACT_5349] (IMO -2125, ipi[INVESTIGATOR_125], and pembrolizumab), dose , 
and time, as appropriate.  
Dose proportionality using the power model will be evaluated in an exploratory manner, if the 
data permit. If insufficient data are available to assess dose proportionality using the power 
model, dose normalized data will be presented for a graphical asse ssment.  
The potential effects of IMO -2125 on the PK of ipi[INVESTIGATOR_707164].  
16.6. Analysis of Efficacy  
The primary analysis of efficacy in the Phase 2 IMO -2125 + ipi[INVESTIGATOR_44772], including the 
hypothesis test of the ORR, will be performed on the first 21 patients  in the PI[INVESTIGATOR_707220]  16.2. An analysis on those in the SIIEE Population will also be performed; 
efficacy analysis in the combined PI[INVESTIGATOR_707221]. The 
primary analysis of efficacy in the Phase 2 IMO -2125 + pembrolizumab arm will be performed 
on the PPI[INVESTIGATOR_707222]  16.2.  
Patients will be categorized into subgroups based on whether they had  previously been treated 
with talimoge ne or another oncolytic viral vector prior to enrollment in this study.  
IMO -2125  Page 85 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960916] with Î± = 0.[ADDRESS_960917] the null rates of 0.11 and 0.05 for ipi[INVESTIGATOR_707223], respe ctively (Hodi, 2010) . ORR by [CONTACT_393] v1.[ADDRESS_960918] 95% confidence 
intervals . DCR will also be summarized by [CONTACT_393]  v1.1. 
The OS and PFS proportions will be estimated  at 6 and 12 months ; OS and PFS will also be 
analyzed overal l. For time -to-event endpoints (OS, PFS, and DoR), the Kaplan- Meier method 
will be used to estimate the probability of event- free survival . Patients who have not experienced 
the event at the data cut -off date for study closure  will be censored . Patients who are lost to 
follow up will be censored at the last valid disease assessment for PFS and date of last contact 
[CONTACT_707242] . Kaplan -Meier plots will be produced for OS and PFS by [CONTACT_2939] . 
16.7. Exploratory Analyses  
Patterns of missing data will be des cribed for PRO . Mean change from B aseline in the global 
health status score over time will be summarized and presented graphically. A mixed model for 
repeated measures may be used to assess the statistical significance of changes from B aseline. 
Exploratory  endpoint analyses will be fully  described in the statistical analysis plan.  
IMO -2125  Page 86 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960919] udy, 
unless the patient withdraws consent. If a patient  discontinues the study ( for any reason, 
drug- related or other), every effort w ill be made to complete the SFU  Visit within [ADDRESS_960920] dose  (Â±5 days) .  
All required data for this study will be collected by [CONTACT_707269] a ll data collected in this study will 
be listed in the clinical study report.  
17.2. Data Collection and Tracking  
Qualified study staff at each site will perform primary data collection  from source -document 
reviews. The designated CRO will perform clinical monitor ing, including review of eCRFs with 
verification to the source documentation. 
Safety l aboratory and ECG data from the S creening V isit through the SFU  Visit will be collected 
at the participating site . A Central Lab may be us ed to track and analyze the comp lement,  PK 
and i mmunogenicity testing .  
Site staff will enter data into a 21 CFR Part 11 compliant eCRF. The frequency and procedures 
for the handling of data within the clinical database will be documented in detail in the Data 
Management Plan.   
IMO -2125  Page 87 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    18. STUDY RES PONSIBILITIES  
18.1. Investigator Responsibilities  
The Investigator should not deviate from the protocol. In medical emergencies, the Investigator 
may use his/her medical judgment and may remove a study participant from immediate hazard 
before notifying Idera Pharmaceuticals, Inc. (or its representative) and the IRB /EC in writing 
regarding the type of emergency and the course of action taken.  
18.2. Study Data Reporting and Processing  
The eCRF wil l be reviewed by [CONTACT_54421] I nvestigator (PI) at the site. The PI [INVESTIGATOR_707224].  This review 
and sign- off may be delegated to a qualified physician appointed as a sub- investigator by [CONTACT_978]. 
The transfer of duties to a sub- investigator will be recorde d on the delegation list (kept on file at 
the site) and all sub -investigato rs are to be listed on appropriate regulatory forms (e.g., FDA 
Form  1572) . The I nvestigator must ensure that all site staff involved in the conduct of the study  
are trained  on and f amiliar with the protocol and all study -specific procedures and that they have 
appropriate knowledge of the study agents.  
18.3. Training  
The training of appropriate clinical site personnel will be the responsibility of  the designated 
CRO . The PI [INVESTIGATOR_53470] f or ensuring that his or her staff conducts the study according to the 
protocol. To ensure proper administration of study agents, uniform data collection, and protocol 
compliance, the designated CRO  will present a formal training session to study site perso nnel, to 
include instructions for study procedures, the investigational plan, instructions on in- hospi[INVESTIGATOR_707225], methods for soliciting data from alternative sources, schedules for follow up with 
the study site coordinators, and regulatory requir ements. Detailed feedback regarding completion 
of forms will be provided by [CONTACT_707270].  
18.4. Monitoring the Investigational Site  
Monitoring of the study (which may be delegated by [CONTACT_328769] a CRO) will be performed 
according to the Study Monitoring Plan. 
18.5. Study Documentation  
Study documentation includes all e CRFs, source documents, monitoring logs, appointment 
schedules, Sponsor -Investigator correspondence, and regulatory documents (e.g., signed protocol 
and amendments, IRB /EC correspondence and approval, approved and signed patient consent 
forms, Statement of Investigator form, and clinical supplies receipts and distribution rec ords).  
The I nvestigator will prepare and maintain complete and accurate study documentation in 
compliance with Good Clinical Practice ( GCP ) standards and applicable regional, federal, state, 
and local laws, rules, and regulations; and, for each patient par ticipating in the study, will 
promptly complete all e CRFs and such other reports as required by [CONTACT_707271] -2125  Page 88 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960921] and also will be made available at the I nvestigatorâ€™s site upon request for 
inspection, copying, review, and audit at reasonable times by [CONTACT_707272], Inc. or responsible government agencies as required by [CONTACT_2371]. The 
Investigator agrees to promptly take any reasonable steps that are requested by 
[CONTACT_707273], Inc. or the designated CRO as a result of an audit to cure deficiencies in 
the study documentation and e CRFs.  
18.6. Source Documentation  
Source documents include all recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical study. 
Accordingly, source documents include, but are not limited to, laboratory reports, ECG tracings, 
x-rays, radiologist reports, patient diaries, biopsy reports, ultrasound photographs, patient 
progress notes, hospi[INVESTIGATOR_1332], pharmacy records (including drug preparation worksheets), and 
any other similar reports or records  of any procedure performed in accordance with the protocol.  
Whenever possible, the original recording of an observation should be retained as the source 
document; however, a photocopy is acceptable provided that it is a clear, legible, and exact 
duplicati on of the original document. 
Regulations require that I nvestigators maintain information in the study patientâ€™s medical records 
that corroborates data collected on the e CRF. In order to comply with these regulatory 
requirements, the following information w ill be maintained and made available as required by 
[CONTACT_707274], auditors, and/or regulatory inspectors:  
1. Medical history/physical condition of the study patient before involvement in the study 
sufficient to verify protocol entry criteria  
2. Medical record documenting that informed consent was obtained for the patientâ€™s 
participation in the study  
3. Dated and signed notes for each patient visit, including results of examinations  
4. Notations on abnormal lab results and their resolution 
5. Dated printouts or repor ts of special assessments (e.g., ECG reports)  
6. Description of AEs and follow up of the AEs (minimally, event description, severity, 
onset date, duration, relation to study device, outcome, and treatment for AE)  
7. Notes regarding concomitant medications taken during the study (including start and stop 
dates)  
8. Patientâ€™s condition upon completion of or withdrawal from the study  
IMO -2125  Page 89 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960922] results. All completed e CRFs will be reviewed  by a 
representative of the designated CRO  at regular intervals according to the Study Monitoring P lan 
as the study proceeds.  
The I nvestigator will mai ntain the records of study drug  disposition, final eCRF s, worksheets, 
and all other study -specific documentation, e.g., study file notebooks or source documentation, 
until notified by [CONTACT_707244], Inc. that records may be destroyed . Idera 
Pharmaceutical, Inc. retains the right to evaluate imaging studies used to make efficacy 
assessments, including central imaging facility review.  
The Investigator(s) must maintain all Essential Documents (as listed in the International Council 
for Harmonisation [ICH] Guideline for GCP) until notified by [CONTACT_707244], Inc. or its 
designees , and in accordance with all local laws regarding ret ention of records. 
The Investigator must obtain written permission from Idera Pharmaceuticals, Inc. or its designees 
before disposing of any records. To avoid error, the Investigator will contact [CONTACT_58436], Inc. before the destruction of any records pertaining to the study . The 
Investigator will promptly notify Idera Pharmaceuticals, Inc. or its designees in the event of 
accidental loss or destruction of any study records . In addition, Idera Pharmaceuticals, Inc. will 
be contact[CONTACT_707275].  
18.10.  Study Closeout  
Upon completion of the study (defined as all patients have completed all follow -up visits, all 
eCRF s are complete, and all queries have been  resolved), the designated CRO will notify the site 
of closeout, and a study closeout visit will be performed. All unused study materials will be 
collected and returned to Idera Pharmaceuticals, Inc. or the designated CRO. The study monitor 
will ensure tha t the I nvestigatorâ€™s regulatory files are up to date and complete, and that any 
outstanding issues from previous visits have been resolved. Other issues to be reviewed at the 
closeout visit include: discussing retention of study files, possibility of site audits, publication 
policy, and notifying the IRB /EC of study closure.  
IMO -2125  Page 90 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    18.11.  Audit/Inspections  
Quality assurance personnel from Idera Pharmaceuticals, Inc., or its partners, may conduct audits 
at the study site. Audits will include, but not be limited to: audit trail of data handling and 
processes, standard operating procedures, drug supply, presence of required documents, the 
informed consent process, and comparison of the eCRF  with source documents . The I nvestigator 
agrees to accommodate and participate in audi ts conducted at a reasonable time in a reasonable 
manner, as needed.  
Regulatory authoritie s worldwide may conduct inspections of  the I nvestigator during or after the 
study . The I nvestigator should contact [CONTACT_707244], Inc. immediately if this occ urs and 
must fully cooperate with Regulatory Authorities  inspections  conducted at a reasonable time in a 
reasonable manner.  
Idera Pharmaceuticals, Inc. retains the right to conduct independent review of radiologic scans 
for up to 3 years following completion of the study. 
 
IMO -2125  Page 91 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960923] the study in compliance with the 
protocol, the International Council for  Harmonisation  (ICH) GCP guidelines, the Declaration of 
Helsinki, and all applicable federal, state, and local laws, rules, and regulations relating to the 
conduct of the clinical study.  
19.1. Role of Sponsor  
As the study Sponsor , Idera Pharmaceuticals, Inc. has overall responsibility for the conduct of 
the study, including assurance that the study meets the regulatory requirements. In this study, 
Idera Pharmaceuticals, Inc. will have certain direct responsibilities and will delegate other 
responsibilities to  the designated CRO . The CRO will ensure adherence to the Sponsor â€™s general 
responsibilities and other responsibilities as agreed between the designated CRO and Idera 
Pharmaceuti cals, Inc., e.g., selection of I nvestigators, monitoring, and protocol amendments . 
19.2. Informed Consent  
The I nvestigator has both ethical and legal responsibili ty to ensure that each patient being 
considered for inclusion in this study is given a full explanation of the study. Written informed 
consent will be obtained from all patients (or their guardians or legal representatives) before any 
study -related procedu res (including any pre -treatment procedures, such as pre- procedure 
sedation) are performed or given.  
Written informed consent will be document ed on an ICF  approved by [CONTACT_78626] /EC 
responsible for approval of this protocol. The ICF will conform to ICH G CP guidelines and to 
the institutional requirements for informed consent a nd applicable regulations. The I nvestigator 
agrees to obtain approval from Idera Pharmaceuticals, Inc. of any ICF intended for use in the 
study, prior to submission for IRB /EC approval.  
The consent form will be reviewed with the prospective study patient or his or her  legal 
representative, and the I nvestigator or qualified designee will be available to answer questions 
regarding procedures, risks, and alternatives.  
Once the ap propriate essential information has been provided to the pati ent and fully explained 
by [CONTACT_941] I nvestigator or qualified designee, and it is felt that the patient understands the 
implications of participating, the patient and the I nvestigator or designee will  sign and date the 
IRB/EC-approved written ICF. The patient will receive a copy of the signed ICF. The original 
signed and dated ICF will be kept in the siteâ€™s regulatory file. Documentation of the patientâ€™s 
informed consent for and participation in this s tudy will be noted in the patientâ€™s medical record.  
If the patient is illiterate, an impartial witness is required to be present during the entire informed 
consent reading and discussion. Afterward, the patient should be asked to sign and date the ICF, 
if capable. The impartial witness should also sign and date the ICF along with the individual who 
read and discussed the informed consent (i.e., study staff personnel).  
The patient or his or her legally acceptable representative will be informed in a timely manner if 
new information becomes available that may be relevant to the patientâ€™s willingness to continue 
IMO -2125  Page 92 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960924] that ensures the 
information can always be tracked back to the source data. For this purpose, a unique patient 
identification code (ID number and patient name [CONTACT_104846]) will be used that allows ident ification of 
all data reported for each patient.  
Patient information collected in this study will comply with the standards for protection of 
privacy of individually identifiable health information as promulgated in the Health Insurance 
Portability and Acc ountability Act ( HIPAA ) and as mandated in 45 CFR 160 and 164. All 
records will be kept confidential and the patientâ€™s name [CONTACT_546161]. Patient 
records will not be released to anyone other than Idera Pharmaceuticals, Inc. or its desig nees, and 
responsible regulatory authorities, when requested. In all cases, caution will be exercised to 
assure the data are treated confidentially and that the patientâ€™s privacy is guaranteed.  
19.4. Authorization for Use and Disclosure of Protected Health 
Infor mation  
An authorization for use and disclosure of protected health information (PHI) under the HIPAA 
Privacy Rule (45 CFR 164.102 et seq) will be obtained from every study  patient before, or at the 
time of, enrollment. It will be presented to, and signed b y, the patient at  the same time as the 
ICF. The I nvestigator is responsible for obtaining patientsâ€™ (or their legal representativesâ€™) 
authorizations and signatures and for explaining the elements of the HIPAA authorization form if 
necessary.  
The HIPAA auth orization may be either a separate form or included in the study ICF, dependent 
upon local requirements. If a separate HIPAA document is signed, the Investigator will append 
one signed original of each executed HIPAA authorization to the study  patientâ€™s signed ICF and 
file it in the siteâ€™s regulatory file. If a second copy of the signed ICF is filed in the patientâ€™s 
medical records, an additional copy of the signed HIPAA authorization form will be appended. 
Patients will be given the other signed duplicate for their personal records.  
The HIPAA authorization form will contain all elements required under the HIPAA Privacy 
Rule. By [CONTACT_2371], site IRB /EC approval of the Sponsor -provided authorization form for use in this 
study is not required, and no such approval wi ll be sought or requested. However, Idera 
Pharmaceuticals, Inc., upon request, will provide advance copi[INVESTIGATOR_707226] H IPAA authorization 
form to the I nvestigator or the siteâ€™s privacy board or privacy official and will work with the site 
to eliminate any conc erns.  
The I nvestigator or the site will promptly inform Idera Pharmaceuticals, Inc. of any restrictions 
on the use or disclosure of PHI of any pa tient to which the site or the I nvestigator have agre ed 
under the Privacy Rule. The I nvestigator or the site will also promptly inform Idera 
Pharmaceuticals, Inc. of any written revocation of any patientâ€™s HIPAA authorization.  
IMO -2125  Page 93 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960925] serum - and urine -human chorionic 
gonadotropin testing before enrol lment in order to avoid potential fetal exposure. Cognitively 
impaired individuals, prisoners, or  other institutionalized persons will be allowed to participate 
only after documented consultation with the IRB /EC. 
Patients who are iden tified will be referre d to the I nvestigato r or authorized designee for 
screening. Patients will then undergo the  screening process, during which they will have multiple 
opportunities to ask questions. The PI [INVESTIGATOR_707227] a detailed discussion 
of the protocol and answer any remaining questions. The patient will be given time to consider 
study participation. No coercion or undue influence on this decision will be used. Only those  
patients who give written, informed consent, meet prescreening requirements, and successfully 
complete screening testing before the date of planned study drug administration will be 
considered for participation in the study. Specific consent is required for serum samples to be 
stored for future studies in coagulation and inflammation. Participation in the study is not 
contingent upon a patientâ€™s agreement to provide additional serum samples. 
Blood specimens will be coded to ensure patient confidentiality.  
19.5.2. Risks/Discomforts of Study Participation  
IMO -2125 is designed to stimulate the immune system and some low -grade and transient signs 
and/or symptoms may occur:  
â€¢ Low-grade elevation in body temperature  
â€¢ Mild headache  
â€¢ Chills  
â€¢ Diaphoresis  
â€¢ Myalgia  
â€¢ Fatigue  
In addition, patients may experience some or none of the following manifestations of local site 
injection reactions:  
â€¢ Erythema (characteristically maximal by [CONTACT_707276]) 
â€¢ Induration (sometimes persisting for up to 1 week)  
â€¢ Pain (usually mild and requiring no treatment)  
â€¢ Tenderness to the touch  
Patients will undergo the study procedures detailed in Section  9, some of which can be expected 
to cause mild discomfort.  
IMO -2125  Page 94 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960926] be reviewed and approved by [CONTACT_2717]/EC, applicable regulatory authorities, and 
host institution(s) for written approval (where applicable) bef ore enrollment of patients and 
release of investigational product . Documentation of IRB/EC approval and the approved consent 
form must be received by [CONTACT_707244], Inc. or its designees prior to obtaining the 
patientâ€™s  informed consent . Amendments  to the original approved documents, where applicable, 
will also be submitted to and approved by [CONTACT_707277] . Investigators will comply with the 
appropriate IRB/EC reporting requirements.  
19.7. Financial Disclosure  
In compliance with 21 CFR 54.4, any liste d or identified Investigator  or sub -investigator 
(including the spouse and any dependent children of said individuals) directly involved in the 
treatment or evaluation of research patients will disclose required  information for the time period 
during which the Investigator  is participating in the study and for 1 year fo llowing completion of 
the study.  
  
IMO -2125  Page 95 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960927] OF REFERENCES 
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European 
Organisation for Research and Treatment of Cancer QLQ -C30: A quality -of-life instrument for 
use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365- 376. 
Abreu  MT. Toll -like receptor signaling  in the intestinal epi[INVESTIGATOR_2130]: how bacterial recognition 
shapes intestinal function . Nat Rev Immnol. 2010;10:131- 144. 
Aspord C, Leccia MT, Charles J, Plumas J. Plasmacytoid dendritic cells support melanoma 
progression by [CONTACT_707278]2 and regulatory immunity through OX40L and ICOSL. Cancer 
Immunol Res. 2013;1:402- 415. 
Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High- dose recombinant interleukin- 2 therapy in 
patients with metastatic melanoma: long -term survival update. Cancer J Sci. 
2000;Am  6 (Suppl  1): S11 -4. 
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High- dose 
recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 
270 patients treated between 1985 and 1993. J Cl in Oncol. 1999;17: 2105- 2116. 
Baines J, Celis E. Immune -mediated tumor regression induced by [CONTACT_637622] -containing 
oligodeoxynucleotides. Clin Cancer Res. 2003;9:2693- 2700. 
Bernasconi N, Traggiai E, Lanzavecchia A. Maintenance of serological memory by [CONTACT_707279] B cells. Science. 2002;298:2199- 2202. 
Bhagat, L. Time dependent cytokine secretion by [CONTACT_707280] -2125 treatment. Idera Study. 2007a;Number PH2125- 012. 
Bhagat, L. Time dependent cytokine secretion by [CONTACT_707281] -2125 treatment. Idera Study. 2007b;Number PH2125- 012A. 
Bhagat L. Time dependent cytokine  secretion by [CONTACT_707282] -2125 
treatment. Idera Study. 2007c ;Number PH2125- 015A. 
Bhagat L. To test the concentration dependent effect of IMO -2125 on IFN -a secretion by [CONTACT_707283]. Idera Study. 2007d;Number PH2125- 016. 
Bhagat L. To test the concentration dependent effect of IMO -2125 on IFN -a secretion by [CONTACT_707284]. Idera Study. 2007e ;Number PH2125- 019. 
Bhagat, L. To test the concentration dependent effect of IMO -2125 in human B -cell proliferation 
assays. Idera Study. 2007 f;Number PH2125- 026. 
Bhagat, L. Activation of human B -cells by [CONTACT_58444] -2125: A flow cytometry study. Idera Study. 
2007g ;Number PH2125- 027. 
Bhagat, L. Activation of human pDCs by [CONTACT_58444] -2125: A flow cytometry study. Idera Study. 
2007h;Number PH2125- 028. 
Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an ove rview. Oncology . 
2009;23:488- 496. 
IMO -2125  Page 96 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Bohnsack O, Ludajic K, Hoos A . Adaptation of the immune -related response criteria: irRECIST. 
Ann Onc. 2014;25(Suppl -4):iv361- iv372. 
Brunet JF, Denizot F, Luciani MF, Roux -Dosseto M, Suzan M, Mattei MG, et al. A new member 
of the immunoglobulin superfamily --CTLA -4. Nature. 1987;328(6127):267- 270. 
Chan E, Kwak EL, Hwang J, Heiskala M, de La Bourdonnaye G, Mita M. Open- label phase 1b 
study of FOLFIRI plus cetuximab plus IMO -[ADDRESS_960928] 
progressed following chemotherapy for advanced or metastatic disease. Cancer Chemother 
Pharmacol. 2015 Jan 28. [Epub ahead of print] . 
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 3, 14 June 2010. U.S. 
Department of Health and Human Services, National Institutes of Health, National Cancer 
Institute. NIH Publication No. 09- 5410.  
den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, et al. In situ 
tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 
2004;64:4024- 4029. 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in sol id tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 
2009;45:228- 247. 
Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, JahrsdÃ¶rfer B, et al. Peritumoral CpG 
DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established 
tumors in a murine colon carcinoma model. J Immunol. 2002;169:3892- 3899. 
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved 
survival with ipi[INVESTIGATOR_707228]. N Engl J Med. 
2010;363:711- 723. 
Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, et al. Divergent synthetic nucleotide 
motif recognition pattern: design and development of potent immunomodulatory 
oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nuclei c Acids Res. 
2003;31(9):2393- 2400.  
Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, et al. Immunomodulatory 
oligonucleotides containing a cytosine -phosphate -2'-deoxy -7-deazaguanosine motif as potent 
toll-like receptor 9 agonists. Proc Natl Acad Sci [LOCATION_003]. 2005;102(19):6925- 6930. 
Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flahert y LE, Ernstoff MS,  et al. High - and 
low-dose interferon alfa -2b in high- risk melanoma: first analysis of intergroup trial 
E1690/S9111/C9190. J Clin Oncol. 2000;18:2444- 2458. 
Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Epi[INVESTIGATOR_707229], epi[INVESTIGATOR_623], and end results program. J Invest Dermatol. 
2008;128:1340- 1342.  
Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipi[INVESTIGATOR_456173]. N Engl J Med. 2015;373(13):1270- 1.  
IMO -2125  Page 97 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress 
naive and memory T cell proliferation and can be expanded in vitro without loss of function. 
J Exp Med. 2001;193:1295- 1302. 
Liu YJ. IPC: professional type 1 interferon -producing cells and plasmacytoid dendritic cell 
precursors. Annu Rev Immunol. 2005;23:275- 306. 
Lou Y, Liu C, LizÃ©e G, Peng W, Xu C, Ye Y, et al. Antitumor activity media ted by [CONTACT_637622]: the 
route of administration is critical. J Immunother. 2011;34:279- 288. 
Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, Ruers TJ, et al. Route of 
administration of the TLR9 agonist CpG critically determines the efficacy of cancer  
immunotherapy in mice. PLoS One. 2009;4:e8368. 
Nishino M, Giobbie -Hurder A, Gargano M, et al. Developi[INVESTIGATOR_007] a common language for tumor 
response to immunotherapy: immune -related response criteria using unidimensional 
measurements. Clin Cancer Res. 2013;19(14 ):3936- 43. 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and 
response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649- 655. 
Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. 
CTLA -[ADDRESS_960929] mechanisms . Mol Cell Biol. 
2005;25(21):9543- 9553.  
Postow MA, Chesney J, Pavlick AC, Robert C, Grossman K, McDermott D, et al. Nicolumab 
and ipi[INVESTIGATOR_707230] u ntreated melanoma. N Engl J Med. 
2015;372(21):2006- 17. 
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus 
Ipi[INVESTIGATOR_55538]. N Engl J Med. 2015;372(26):2521- 2532. 
Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: whatâ€™s here, whatâ€™s 
next? Curr Opin Immunol. 2015;33:23- 35. 
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin. 2015;65(1):5- 29. 
Smith DA, Conkling P, Richards DA, Nemunaitis JJ, Boyd TE, Mita AC, et al. Antitumor 
activity and safety of combination therapy with the Toll -like receptor [ADDRESS_960930] progressed following chemotherapy. Cancer Immu nol Immunother. 2014;63(8):787- 796.  
[COMPANY_005] K, Akira S. Toll -like receptors in innate immunity. Int Immunol. 2005;Jan;17(1):1- 14. 
Thall PF, Cook JD, Estey E. Adaptive dose selection using efficacy -toxicity trade -offs: 
illustrations and practical considerat ions. J Biopharm Stat. 2006;16(5):623- 638. 
Trombino AF. A report of cytometry and hematology analyses from samples collected in 
immunopharmacological screening of oligonucleotide test articles in cynomolgus monkeys. Idera 
Study. 2007a;Number PH2125- 006. 
Trombino AF. Report of cytokine, flow cytometry and hematology analyses from samples 
collected in immunopharmacological screening of oligonucleotide test articles in cynomolgus 
monkeys: IMO -2125, experiments 1, 2 and 3. Idera Study. 2007b;Number PH9999- 007. 
IMO -2125  Page 98 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD -1 blockade 
induces responses by [CONTACT_404356]. Nature. 2014; 515(7528):568- 571. 
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et a l. CTLA -4 can 
function as a negative regulator of T cell activation. Immunity. 1994;1:405 -413. 
Wickelgren I. Targeting the tolls. Science. 2006;312:184- 187. 
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, LebbÃ© C, et al. Guidelines for the 
evaluation of immune therapy activity in solid tumors: immune -related response criteria. Clin 
Cancer Res. 2009;15:7412- 7420.  
Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, et al. Potent CpG oligonucleotides 
containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem 
Biophys Res Commun. 2002;297(1):83- 90. 
Zamarin D, Postow MA. Immune checkpoint modulation: Rational design of combination 
strategies. Pharmacol Ther. 2015;S0163- 7258. [Epub ahead of print] . 
IMO -2125  Page 99 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    21. APPENDICES  
21.1. Eastern Coope rative Oncology Group  
ECOG Performance Status : 
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. 
Up and about more than 50% of waking hours  
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours  
4 Completely dis abled. Cannot carry on any self care. Totally confined to bed or chair  
5 Dead  
 
IMO -2125  Page 100 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    21.2. Immune -Related Response Criteria (irRC)  
During Phase 1, subject management and response assessments will be performed according to 
irRC (Wolchok, 2009) .  
Appendix  Table  1: Overall Response using irRC:  
Response assessment  Description  
irCR  Complete disappearance of all lesions (whether measurable or 
not, and no new lesions)  
Confirmation by a repeat, consecutive assessment 
â‰¥[ADDRESS_960931] documentation  
irPR Decrease in tumor burden â‰¥50% relative to baseline  
Confirmed by a consecutive assessment â‰¥ [ADDRESS_960932] documentation  
irSD  Not meeting criteria for irCR or irPR, in absence of irPD . 
A change in tumor burden of neither 50% decreas e from 
baseline nor 25% increase from nadir can be determined.  
irPD  Increase in tumor burden â‰¥25% relative to nadir (minimum 
recorded tumor burden)  
Confirmation by a repeat, consecutive assessment 
â‰¥[ADDRESS_960933] documentation  
Abbreviations: CR=complete response; irRC=Immune -related Response Criteria; PD=progressive disease; 
PR=partial response; SD=stable disease  
 
Appendix  Table  2: Derivation of irRC overall responses  
Measurable response  Non-measurable response   
Target and new, 
measurable lesions  
% change in tumor 
burden  Non-target lesions  New non- measurable 
lesions  Overall irRC response  
â†“ 1001 Absent  Absent  irCR3 
â†“ 1001 Stable  Any irPR3 
â†“ 1001 Unequivocal progression  Any irPR3 
â†“ â‰¥501 Absent or Stable  Any irPR3 
â†“ â‰¥501 Unequivocal progression  Any irPR3 
â†“ â‰¥50 to   â†‘<251 Absent or Stable  Any irSD  
â†“ â‰¥50 to   â†‘<251 Unequivocal progression  Any irSD  
â†‘ â‰¥252 Any Any irPD3 
1  Decrease relative to baseline  
2  Increase relative to nadir  
3  Confirmed by [CONTACT_707285] â‰¥[ADDRESS_960934] documentation  
 
IMO -2125  Page 101 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960935] (Immune -Related Response Evaluation Criteria in Solid 
Tumors)  
In Phase [ADDRESS_960936] (Nishino, 2013; Bohnsack, 2014). For irRECIST, a unidimensional 
measurement is assessed for the longest diameter of each lesion.  
Target lesion:  â‰¥[ADDRESS_960937] diameter (target nodal lesion â‰¥[ADDRESS_960938] diameter), 
representative of the organs involved, and lend themselves to reproducible repeated 
measurements. Baseline target lesions are limited to a total of [ADDRESS_960939] shown unequivocal progression after the radiation. 
Non-target lesion:  all other lesions, including small lesions (<[ADDRESS_960940] diameter or 
nodal lesi ons â‰¥10 mm and <[ADDRESS_960941] diameter) and all truly non -measurable lesions.  
Tumor burden:  the sum of the longest diameters of all baseline target lesions (use shortest 
diameter for target nodal lesions) and all measurable new lesions.  
Appendix  Table  1: Overall Response using irRECIST  
Response assessment  Description  
irCR  â€¢ Complete disappearance of all lesions (and no new measurable or 
non-measurable lesions).  
â€¢ Pathological lymph nodes (target or non -target) must have 
diameter <10  mm in short axis.  
â€¢ Requires confirmation by [CONTACT_707286] â‰¥[ADDRESS_960942] documentation . 
irPR â€¢ â‰¥30% decrease in tumor burden from baseline.  
â€¢ No unequivocal progression of baseline non- target lesions.  
â€¢ No unequivocal progression of new, non- measurable lesions. 
â€¢ Requires confirmation by [CONTACT_707286] â‰¥[ADDRESS_960943] documentation . 
irSD  â€¢ Not meeting criteria for irCR or irPR, in absence of irPD . 
irPD  â€¢ â‰¥20% increase in tumor burden from nadir (the minimum 
recorded tumor burden).  
â€¢ The presence of new, measurable lesions does not define 
progression. New measurable lesions are added to the assessment 
of tumor burden.  
â€¢ A substantial, unequivocal worsening of baseline non- target 
lesions is indicative of irPD.  
â€¢ A substantial, unequivocal worsening of new, non -measurable 
lesions is indicative of irPD.  
â€¢ Requires confirmation by [CONTACT_707286] â‰¥[ADDRESS_960944] documentation . 
irCR=immune -related complete response; irPD=immune -related progressive disease; irPR=immune -related partial 
response; irRECIS T=Immune -related Response Evaluation Criteria in Solid Tumors; irSD=immune -related stable 
disease  
IMO -2125  Page 102 of 106 
Protocol 2125- 204, Version 8.0 Date: [ADDRESS_960945] v1.1 Criteria  
 

IMO -2125  Page 103 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
     

IMO -2125  Page 104 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
     
 

IMO -2125  Page 105 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
     
Appendix  Table  2: Objective Response Status at Each Evaluation  
 
 

IMO -2125  Page 106 of 106 
Protocol 2125- 204, Version 8.0 Date: 27 M arch 2018  
   
 Confidential   
    Appendix  Table  3: Objective Response Status at Each E valuation for Patients with 
Non-Target  Disease Only  
 
 
 
 
 
